

1 **A Phase II Study Integrating a Single-Blind Safety Phase with a Double-Blind,**
2 **Placebo-Controlled Randomized Phase, Assessing Single-Dose Intramuscular**
3 **or Intranasal Administration to Evaluate the Safety and Immunogenicity of the**
4 **Recombinant Vaccine Against COVID-19 (AVX/COVID-12 "Patria") Based on an**
5 **Active Newcastle Disease Viral Vector as a Heterologous Booster in Subjects**
6 **with Evidence of Previous Immunity to SARS-CoV-2.**

7 Constantino López-Macías^{1*}, Martha Torres², Brenda Armenta-Copca³, Niels
8 Wachter⁴, Laura Castro-Castrezana⁵, Andrea Alicia Colli-Domínguez⁶, Tania Rivera-
9 Hernández^{1,7}, Alejandro Torres-Flores^{1,8}, Luis Ramírez-Martínez⁹, Georgina Paz-De
10 la Rosa⁹, Oscar Rojas-Martínez⁹, Alejandro Suárez-Martínez⁹, Gustavo Peralta-
11 Sánchez⁹, Claudia Carranza², Esmeralda Juárez¹⁰, Horacio Zamudio-Meza², Laura
12 E. Carreto-Binaghi², Mercedes Viettri², Damaris Romero-Rodríguez¹¹, Andrea
13 Palencia², Edgar Reyna-Rosas², José E. Márquez-García², David Sarfati-Mizrahi⁹,
14 Weina Sun¹², Héctor Elías Chagoya-Cortés¹³, Felipa Castro-Peralta⁹, Peter
15 Palese¹², Florian Krammer^{12,14,15}, Adolfo García-Sastre^{12,15,16,17,18,19} and Bernardo
16 Lozano-Dubernard^{9*}

17 ¹Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de
18 Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro
19 Social (IMSS), Ciudad de México (CDMX), México. ²Laboratorio de Inmunobiología
20 de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER)
21 "Ismael Cosío Villegas", CDMX, México. ³ILS Clinical Research, S.C., CDMX,
22 México. ⁴Unidad de Investigación Médica en Epidemiología Clínica, UMAE Hospital
23 de Especialidades, Centro Médico Nacional Siglo XXI, IMSS, CDMX, México.
24 ⁵CAIMED Investigación en Salud, S. A. de C. V., CDMX, México. ⁶Oaxaca Site
25 Management Organization (OSMO) S.C., Oaxaca, México. ⁷Investigadores por
26 México, Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT),
27 CDMX, México. ⁸Posgrado en Inmunología, Escuela Nacional de Ciencias
28 Biológicas, Instituto Politécnico Nacional, CDMX, México. ⁹Laboratorio Avi-Mex S.A.
29 de C.V., CDMX, México. ¹⁰Departamento de Investigación en Microbiología INER,
30 "Ismael Cosío Villegas", CDMX, México. ¹¹Unidad de Citometría INER, "Ismael
31 Cosío Villegas", CDMX, México. ¹²Department of Microbiology, Icahn School of
32 Medicine at Mount Sinai, New York, NY, USA. ¹³Consultora Mexstrategy, S.A.S. de
33 C.V., CDMX, México. ¹⁴Center for Vaccine Research and Pandemic Preparedness
34 (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA.
35 ¹⁵Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of
36 Medicine at Mount Sinai, New York, NY, USA. ¹⁶Department of Medicine, Division of
37 Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
38 ¹⁷Global Health and Emerging Pathogens Institute, Icahn School of Medicine at
39 Mount Sinai, New York, NY, USA. ¹⁸The Tisch Cancer Institute, Icahn School of
40 Medicine at Mount Sinai, New York, NY, USA. ¹⁹The Icahn Genomics Institute, Icahn
41 School of Medicine at Mount Sinai, New York, NY, USA.

42

43 *Correspondence: lozano@avimex.com.mx (B. Lozano-Dubernard),
44 constantino.lopez@imss.gob.mx (C. López-Macias)

45 **Abstract**

46 **Background:** The global inequity in coronavirus disease 2019 (COVID-19) vaccine
47 distribution, primarily affecting low- and middle-income countries (LMICs), highlights
48 the urgent need for innovative and cost-effective vaccine technologies to address
49 availability disparities. This is crucial for achieving and sustaining widespread
50 immunity and protecting vulnerable populations during future booster campaigns.

51 **Methods:** To address this need, we conducted a phase II clinical trial evaluating the
52 safety and immunogenicity of the AVX/COVID-12 "Patria" vaccine as a booster dose.
53 The vaccine was administered through both intramuscular (IM) and intranasal (IN)
54 routes to participants who had previously received severe acute respiratory
55 syndrome coronavirus 2 (SARS-CoV-2) vaccines based on adenoviral technology,
56 inactivated virus, or mRNA technology. The inclusion criterion involved individuals
57 with initial anti-spike IgG titers below 1,200 U/mL, allowing observation of the booster
58 effect induced by vaccination.

59 **Results:** Immunization with AVX/COVID-12 resulted in a significant (>2.5 times)
60 increase in neutralizing antibodies against the original Wuhan strain and variants of
61 concern (VOCs) such as Alpha, Beta, Delta, and Omicron (BA.2 and BA.5). This
62 immune response was accompanied by cellular interferon-gamma (IFN- γ)
63 production, indicating a robust and multifaceted reaction.

64 **Conclusions:** The administration of AVX/COVID-12 as a booster dose, whether
65 through IM or IN routes, was safe and well-tolerated. The vaccine extended immune
66 responses not only against the original Wuhan-1 strain but also against various
67 VOCs. Its ability to enhance preexisting immune responses suggests a potential
68 contribution to expanding and sustaining herd immunity within the population.

69

70 **Keywords:** COVID-19 vaccine booster, phase II clinical trial, Newcastle disease
71 virus LaSota, SARS-CoV-2.

72 **Introduction**

73 Since 2020, SARS-CoV-2 and its variants have led to widespread infections and
74 millions of deaths worldwide (1). The unequal distribution of vaccines globally,
75 particularly impacting low- and middle-income countries (LMICs), underscores the
76 necessity for developing new vaccine platforms to address distribution disparities
77 (2). Ensuring a high vaccination rate globally is crucial for achieving widespread
78 immunity. There is a strong possibility that administering periodic booster doses in
79 the future will be necessary to prevent subsequent waves of COVID-19.
80 Consequently, the global vaccine supply will continue to be a problem that needs to
81 be addressed.

82 Population protection against COVID-19 is achieved by immunity, which has been
83 extensively developed through a combination of infection and vaccination, including
84 the use of vaccines that employ the spike protein from the original Wuhan-1 variant
85 of SARS-CoV-2 as an antigen. This protection is referred to as "hybrid immunity."
86 Various scientific articles have demonstrated that hybrid immunity is highly effective
87 in primarily preventing hospitalization and death caused by variants of concern,
88 including Omicron and its predominant subvariants, even though protection against
89 infection may have diminished (3,4). In other words, first-generation vaccines remain
90 valuable for strengthening and expanding acquired SARS-CoV-2 immunity, leading
91 the World Health Organization (WHO) to continue recommending their use when
92 vaccines targeting more recent variants are unavailable (5).

93 Supporting this point, it is noteworthy that hospitalization and mortality have
94 significantly decreased since the introduction of vaccination with first-generation
95 vaccines. Some studies report a 25% reduction in the risk of hospitalization and a
96 96% reduction in mortality for each additional dose administered (6). In Mexico, the
97 mortality rate before vaccination was 1.04 per 1,000 inhabitants; after the
98 implementation of vaccination and the development of hybrid immunity, a mortality
99 rate of 0.01 per 1,000 inhabitants has been achieved in the sixth wave, despite being
100 caused by different VOCs, including Omicron (7).

101 Unfortunately, the mutation rate of SARS-CoV-2 has been until now faster than our
102 capacity to generate updated vaccines. Nevertheless, it is desirable to develop
103 vaccines as close as possible to the circulating strains, aiming to protect not only
104 against hospitalization and death but also against symptomatic disease.
105 Furthermore, there is a need for the development of vaccines that prevent
106 transmission. One possibility is the creation of vaccines that induce mucosal
107 immunity to avert the initial viral infection at the site of entrance, such as intranasally
108 administered vaccines.

109 The AVX/COVID-12 vaccine candidate "Patria" utilizes a vector based on the
110 Newcastle disease virus LaSota (NDV-LaSota), expressing a stabilized prefusion
111 conformation version of the spike (S) protein of the SARS-CoV-2, known as HexaPro
112 S (8,9). This vector presents distinct advantages, including a standardized
113 production process in embryonated chicken eggs, a method commonly used in
114 influenza vaccine manufacturing. This approach allows for efficient dose generation
115 and provides the added benefit of intranasal administration, further enhancing its
116 usability. The IN administration feature is particularly advantageous, offering an
117 alternative and potentially more accessible method of delivery compared to
118 traditional IM routes. This characteristic is desirable to expand vaccination coverage,
119 especially in areas with low immunization rates or incomplete vaccination schedules.

120 The NDV-LaSota vector expressing HexaPro S elicited a strong immune response
121 with IgA, IgG2a antibodies, and IFN- γ -producing T cells when used in mice and

122 hamsters, providing complete protection against SARS-CoV-2 challenge. Trials in
123 pigs assessed AVX/COVID-12 safety and immunogenicity via IM and IN
124 administration, revealing no inflammation, fibrosis, or abscesses at the application
125 site. The study demonstrated robust serum-neutralizing antibodies, cross-reactivity
126 to spike protein epitopes in VOCs, and overall safety without signs of viral infection
127 (10,11).

128 In a phase I clinical trial (NCT04871737) that included 91 volunteers, AVX/COVID-
129 12's safety and immunogenicity were assessed with various prime-boost regimens
130 administered IM and IN. Three 50% embryo infective doses (EID_{50%}) (Low: 10^{7.0}
131 EID_{50%}, Middle: 10^{7.5} EID_{50%} or High: 10^{8.0} EID_{50%}) were well-tolerated, with minimal
132 reactogenicity. No serious adverse events were associated with any route or dose,
133 confirming the vaccine's safety and immunogenic profile (12). The study laid the
134 foundation for subsequent clinical development.

135 In this study, we assessed the safety and immunogenicity of the AVX/COVID-12
136 vaccine in a phase II clinical trial. Administered as a booster dose (both IM and IN),
137 AVX/COVID-12 was given to participants who had previously received SARS-CoV-
138 2 vaccines based on adenoviral technology, inactivated virus, or mRNA technology,
139 primarily with initial anti-S IgG titers below 1,200 U/mL. These titers were considered
140 low enough to observe the booster effect induced by the IM and IN administration of
141 AVX/COVID-12.

142 **Material and methods**

143 **Study design**

144 A phase II study (ClinicalTrials.gov #NCT05205746) was conducted to assess the
145 safety phase under single-blind conditions, followed by randomized, double-blind,
146 placebo-controlled, single-dose administration via IM or IN routes, in subjects with
147 evidence of prior immunity to SARS-CoV-2. This was followed by an assessment
148 phase to evaluate the booster response, involving an IM dose of the COVID-19
149 vaccine (recombinant AZ/ChAdOx-1-S) in subjects originally randomized to the
150 placebo arm.

151 The protocol was formulated by iLS Clinical Research, S.C. in collaboration with the
152 Mexican Institute for Social Security (IMSS) and Laboratorio Avi-Mex, S.A. de C.V.
153 (Avimex®), which was the sponsor. Approval for the study was granted by the
154 Federal Commission for the Protection against Sanitary Risks (COFEPRIS) in
155 Mexico, assigned the number RNEC2021-AVXSARSCoV2VAC002. Ethics approval
156 was obtained from the institutional ethics committee at each research site
157 participating in the study. The research was conducted in complete compliance with
158 Mexican regulations and by the principles outlined in the Declaration of Helsinki and

159 Good Clinical Practice. Immunological assay samples were processed at the
160 National Institute for Respiratory Diseases (INER) in Mexico City.

161 **Study groups**

162 The study groups included adults aged 18 years or older of both genders who signed
163 informed consent and had not experienced respiratory issues in the 21 days
164 preceding the administration of the single dose. Participants committed to
165 maintaining appropriate preventive measures to avoid SARS-CoV-2 infection
166 throughout their study participation, particularly during the initial 14 days following
167 the baseline visit. Additionally, eligibility criteria involved having detectable anti-spike
168 IgG titers in serum during the screening visit, with titers levels less than 1,200 U/mL
169 measured in a chemiluminescence test. Furthermore, participants were required to
170 provide evidence of vaccination, with a minimum of 4 months having passed since
171 the last vaccination. Due to the nature of the study, recruited subjects were enrolled
172 in one of three subgroups based on the vaccine technology used during the primary
173 immunization against SARS-CoV-2: subjects with a history of prior immunization with
174 vaccines based on adenoviral technology, inactivated virus, or mRNA technology.

175 The exclusion criteria encompassed hypersensitivity or allergy to any component of
176 the vaccine, a history of severe anaphylactic reactions, a history of seizures,
177 uncontrolled chronic diseases, chronic conditions requiring treatment with
178 immunosuppressive agents or immune response modulators (e.g., systemic
179 corticosteroids, cyclosporine, rituximab, among others), the development of
180 oncological diseases, active participation in or involvement within the last three
181 months in any other clinical or experimental intervention study, use of any drug or
182 herbal supplement in the 30 days preceding the screening evaluation, or alternative
183 medicine (e.g., chlorine dioxide, etc.) aimed at treating or preventing complications
184 or SARS-CoV-2 infection, or any other condition, fever at the time of the screening
185 visit, and having received any vaccine (experimental or approved) in the 60 days
186 prior to the screening visit, except for the influenza vaccine. Exclusion criteria also
187 included having received a blood or blood component transfusion, or being a plasma
188 donor within the 4 months prior to the screening visit, undergoing dialysis or
189 hemodialysis procedures in the last year before the screening visit, working on
190 poultry or gamecock farms, and having a history of substance abuse problems that,
191 in the investigator's judgment, could interfere with the subject's ability to comply
192 adequately with the protocol guidelines.

193 The randomization of volunteers was conducted using a computer-based random
194 assignment system, ensuring blinding throughout the study. Upon signing the
195 informed consent form, each participant received a patient number, encoding all their
196 information in a pseudo-anonymized manner during data collection and becoming
197 fully anonymized during the analysis.

198 The stratification for subject randomization was generated as follows:

199 Safety phase: Involved single-blinded assignment (blinded to the research subject)
200 to the arm receiving the AVX/COVID-12 vaccine for the first three subjects of each
201 specific vaccine recruited in each branch, IM and IN. For this purpose, eight blocks
202 of six vaccines were generated, and to each block, three subjects with the
203 AVX/COVID-12 vaccine and three subjects with placebo were randomly assigned.

204 Double-blind, placebo-controlled randomized phase: subjects with the
205 corresponding vaccination history were randomized to receive a placebo or the
206 AVX/COVID-12 vaccine in either of the two administration modalities (IM or IN).
207 Starting from block 9, blocks of 4 were generated, and each block was randomly
208 assigned 1 subject with IM AVX/COVID-12 vaccine, 1 subject with IN AVX/COVID-
209 12 vaccine, 1 subject with IM placebo, and 1 subject with IN placebo.

210 After 14 days, following the administration of the AVX/COVID-12 vaccine or placebo,
211 the blinding was revealed for subjects who received a placebo. These subjects
212 received an additional dose of the COVID-19 vaccine (AZ/ChAdOx-1-S) IM.

213 **AVX/COVID-12 vaccine preparation**

214 The AVX/COVID-12 vaccine was manufactured in a purpose-built good
215 manufacturing practice (GMP) facility. The recombinant virus was cultivated in 10-
216 day-old specific-pathogen-free (SPF) chicken embryos through inoculation via the
217 allantoic cavity with $10^{3.3}$ EID₅₀/0.1 mL of the production seed. The embryos were
218 incubated for a period of 72 hours (h) at an average temperature of 37 °C and a
219 relative humidity range of 60% to 70%. After this period, the embryos were
220 refrigerated for at least 12 h to sacrifice them. Harvesting of the allantoic fluid (AF)
221 was conducted under aseptic conditions using a vacuum. The AF was clarified
222 through filters with a pore size of 0.8 to 8.0 µm, concentrated by a factor of 10X in
223 300-kDa cassettes, and subjected to diafiltration in 20 volumes of phosphate-
224 buffered saline (PBS). The AF was stored frozen at -70 °C. The AF yielded a titer of
225 $10^{8.67}$ EID₅₀/mL, from which the frozen active vaccines were prepared. The
226 corresponding volumes of purified AF were aseptically mixed with the stabilizer
227 trehalose, monobasic potassium phosphate, dibasic sodium phosphate and
228 monosodium glutamate and homogeneously mixed for 5 minutes using a Teflon bar
229 and a magnetic stirrer. Finally, they were packed in high-density polyethylene
230 bottles. The vaccines were stored at -80 °C.

231 **Safety**

232 Safety was assessed by comparing adverse events (AEs) between placebo and
233 AVX/COVID-12 vaccine groups, considering their severity and relationship to the
234 intervention. While all participants completed the same visits, those assigned to
235 specific groups underwent additional sample collections during visits corresponding

236 to days 0, 14, 42, 90, 180 and 365 of the study. The primary endpoints in the phase
237 II aspects of this trial included solicited local and systemic AEs. The classification of
238 potential AEs and their association with vaccine exposure followed a two-period
239 analysis. The first period included the initial seven days following vaccination, during
240 which AEs were deemed related to the vaccine components. Conversely, reactions
241 occurring after seven days, typically in response to the development of an immune
242 response, constituted the second period of analysis (13).

243 **Sample collection**

244 Venous blood samples were obtained from participants during scheduled site visits
245 for serology tests and cellular response assessments. Using standard phlebotomy
246 procedures, the samples were collected into two sodium heparin tubes and one
247 separator tube (SST BD vacutainer tubes, Franklin Lakes, NJ, USA). Following
248 collection, the samples were transported at room temperature to the INER for
249 immediate processing. All blood samples and products were handled in a BSL-2
250 laboratory, using appropriate personal protective equipment and safety precautions,
251 adhering to processing protocols approved by the Institutional Biosafety Committee.
252 Peripheral blood samples from each volunteer were centrifuged at $2,260 \times g$ at room-
253 temperature for 10 minutes and transported to a biological safety cabinet. Then, for
254 each sample, the serum was recovered, divided into six aliquots of 200 μL , stored in
255 pre-labeled 1.5 mL cryovials according to the established procedure, and frozen at -
256 20°C until use. One aliquot of serum was thawed for each antibody determination,
257 and the remaining portion of each thawed aliquot was discarded as infectious
258 biological material (IBM).

259 **Peripheral blood mononuclear cell (PBMC) isolation**

260 PBMCs were isolated from venous blood collected in sodium heparin tubes (BD
261 vacutainer tubes, Franklin Lakes, NJ, USA). Within four hours of collection, PBMC
262 isolation was conducted by density-gradient sedimentation of whole blood diluted at
263 a 1:2 ratio in Roswell Park Memorial Institute medium (RPMI) 1640 (Lonza, Basel,
264 Switzerland) at room-temperature. The diluted blood was layered over an
265 appropriate volume of Lymphoprep (Axis-Shield, Dundee, UK) at room-temperature.
266 Then, the PBMC were then recovered, cryopreserved in a medium consisting of 10%
267 dimethyl sulfoxide (DMSO; Sigma Aldrich, St. Louis, MO, USA) and 90% heat-
268 inactivated fetal bovine serum (FBS; GIBCO, California, USA), and stored at -80°C
269 until use. For T-cell assays, the thawing process involved warming frozen cryovials
270 at 37°C in a water bath, and cells were resuspended in 5 mL of CTS OpTmizer
271 (GIBCO, California, USA). After a wash with OpTmizer, cells were counted using a
272 Neubauer chamber, and the viability was assessed by trypan blue; cells were
273 resuspended in OpTmizer medium to a density of 4×10^6 cells/mL.

274 The subunit 1 of the spike protein of SARS-CoV-2 (RayBiotech, Peachtree Corners,
275 Georgia, USA) was selected as the primary antigen due to its display of the most
276 immunogenic epitopes of the spike protein. Additionally, it contains the receptor
277 binding domain (RBD) fragment of the virus, which mediates binding to the host
278 receptor angiotensin-converting enzyme 2 (ACE2) in lung cells.

279 **SARS-CoV-2 detection**

280 Sample processing was conducted through nucleic acid extraction, followed by one-
281 step real-time RT-PCR amplification and detection for SARS-CoV-2. A Roche
282 Magnapure instrument (Roche Diagnostics, Basel, Switzerland) was used for viral
283 RNA extraction, and the following ModularDx kits (TIB Molbiol, Berlin, Germany)
284 were employed:

- 285 • 53-0775-96 Sarbeco N-gene detects SARS and SARS-CoV-2
- 286 • 53-0776-96 Sarbeco E-gene detects SARS and SARS-CoV-2
- 287 • 53-0777-96 SARS-CoV-2 RdRP detects SARS-CoV-2

288 **Determination of IgG anti-SARS-CoV-2 binding antibodies**

289 For the determination of total anti-SARS-CoV-2 serum antibodies, a semi-
290 quantitative enzyme-linked immunosorbent assay (ELISA) was employed to detect
291 IgG antibodies to the spike protein subunit 1 domain (ELISA anti-SARS-CoV-2 (IgG);
292 Catalog # 2606-9601 G; EUROIMMUN, Lübeck, Germany). Samples were
293 processed according to the manufacturer's instructions and analyzed on the
294 EUROIMMUN Analyzer I (EUROIMMUN, Lübeck, Germany). Results are reported
295 semi-quantitatively in ELISA ratio, representing a measure of the relative antibody
296 concentration in participants' serum. For the calculation of the relative concentration,
297 the ratio of the extinction value of the control or sample to the extinction value of the
298 calibrator was determined using the following formula: relative concentration (ratio)
299 = (extinction of control or volunteer sample) / (extinction of calibrator).

300 Interpretation of results, in terms of positivity, was conducted according to the
301 manufacturer's instructions:

- 302 • Ratio <0.80: Negative
- 303 • Ratio >0.8 to <1.1: Uncertain
- 304 • Ratio >1.1: Positive

305 To estimate the geometric mean titers (GMT) of the IgG anti-spike subunit 1
306 antibodies in participants' serum, serial dilutions (1:100, 1:300, 1:900, 1:2700,
307 1:5400) were performed for all serum samples with ratio values equal to or greater
308 than 1.1 at the 1:100 dilution. For sera with ratio values < 0.8 at the 1:100 dilution, a
309 titer of 1:20 was assigned for simplified analysis.

310 **Pseudovirus neutralization assay**

311 The presence of neutralizing antibodies was assessed using a microneutralization
312 assay. The assay relies on the inhibition capacity of infection in an *in vitro* model
313 present in serum samples and employed recombinant vesicular stomatitis virus
314 (rVSV) pseudovirus particles expressing the protein from the ancestral Wuhan-1
315 strain, Alpha, Delta, Beta, and the Omicron subvariants BA.2 (clone 1) and BA.5
316 (clone 4) (VSV-eGFP-SARS2) kindly provided by Dr. Sean Whelan (Washington
317 University, USA). The cellular model used to assess the inhibition capacity was the
318 Vero E6 cell line (The American Type Culture Collection (ATCC) CRL-1586,
319 Manassas, VA, USA), which is susceptible to infection as it expresses the
320 recognition receptors for the SARS-CoV-2 spike protein.

321 Before performing the assay (previously validated and established as an analytical
322 method), all serum samples were inactivated at 56 °C for 30 minutes. In 96-well
323 plates, 1.3×10^4 Vero E6 cells (ATCC, Manassas, VA, USA) per well were seeded
324 and incubated for 24 hours at 37 °C, 5% CO₂, allowing them to reach 85%
325 confluence. Next, serum samples were serially diluted 1:2 in FBS-free Eagle's
326 minimal essential medium (EMEM; Rahway, New Jersey, USA) in duplicate, starting
327 with a 1:20 dilution up to 1:1280. Diluted samples were mixed with the concentration
328 of particles of VSV-SARS-CoV-2 S pseudoviruses from the ancestral strain and the
329 aforementioned variants, capable of causing cellular damage at 50% (50% tissue
330 culture infectious dose, TCID₅₀). The mixture was incubated for 60 minutes at 37 °C,
331 5% CO₂. Then, each serum dilution was transferred to a parallel plate containing
332 Vero E6 cells and incubated for 72 h at 37 °C, 5% CO₂.

333 After the incubation period, 3.7% formaldehyde was added and incubated for 30-40
334 minutes at room temperature. The plates were washed twice with PBS, and the
335 recording and analysis of the plates was carried out by optical microscopy,
336 documenting the presence or absence of damage to the monolayer, known as
337 cytopathic effect, at each dilution of the different serum samples. These values were
338 used to calculate the 50% protection level by applying the Spearman-Kärber Method,
339 obtaining the 50% inhibitory dilution (ID₅₀) and the protective titer of each sample.
340 The upper and lower detection limits for neutralizing activity are ID₅₀ > 1.6 and a titer
341 > 1:40 (initial dilution). Each assay included negative and positive infection controls
342 (uninfected cells and infection control inoculated with the reporter vector VSV-eGFP-
343 SARS2 and the subvariants in a suspension containing 100 TCID₅₀). Titers < 1:40
344 (initial dilution) are reported with a value of 20 for statistical analysis.

345 **Evaluation of cytokines in cell culture supernatants**

346 PBMCs were resuspended at a concentration of 2×10^6 cells/mL in CTS OpTmizer
347 medium (GIBCO, California, USA). Duplicate samples of 2×10^5 cells/well were
348 plated in 96-well plates and stimulated with 5 µg/mL of the spike protein subunit 1

349 (RayBiotech, Peachtree Corners, GA), using culture medium as a negative control.
350 After 18 hours of culture, the supernatant was collected, aliquoted, and stored at -20
351 °C until use for cytokine determination. Subsequently, the supernatants were thawed
352 and centrifuged at 14,000 rpm for 10 minutes, and cytokine concentrations were
353 measured using the Th1/Th2 Bio-Plex kit (BIO-RAD, California, USA). This kit allows
354 the quantification using the Bio-Plex 200 system and Bio-Plex Manager 6.1 software
355 (BIO-RAD, California, USA). Values were extrapolated from a concentration curve
356 and expressed in pg/mL.

357 **Hemagglutination inhibition antibody assay for Newcastle disease virus (NDV)**

358 A hemagglutination inhibition assay was performed to assess the presence of
359 inhibitory antibodies against specific hemagglutination of NDV. This method,
360 adapted from the original avian sera procedure, was implemented and validated in
361 our group for human serum analysis. The procedure utilized a system with 1% avian
362 erythrocytes and eight hemagglutinant units (8 HAU/mL) of inactivated NDV antigen
363 (AgNDV, DCV Inc. Lot: 23920103). Briefly, serum samples were inactivated for 30
364 minutes at 56 °C; 100 µL of each sample underwent pre-absorption with an equal
365 volume of a 5% avian erythrocyte suspension and incubated overnight (16-18 h) at
366 2-8 °C. Next, the samples were centrifuged at 1,500 x g for 60 seconds, and the
367 supernatants were collected and stored at -20 °C until use.

368 In 96-well round-bottom plates, 25 µL/well of pre-absorbed serum samples were
369 placed in duplicate, and serial 1:2 dilutions were made (starting with a 1:8 dilution,
370 subsequent dilutions included 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, and 1:1,024).
371 Subsequently, 25 µL/well of AgNDV suspension adjusted to 8 HAU/mL was added,
372 and the samples were incubated (inhibition process) for 30 minutes at room-
373 temperature (19-25 °C). Then, 25 µL of 1% avian erythrocyte suspension was added
374 and incubated for 40 minutes at room temperature (19-25 °C). The interpretation of
375 the plates was performed by placing them at a 45° position to observe the
376 precipitated erythrocytes flowing (teardrop formation). The technique's limit of
377 detection was a titer of 1:4, and the positive cutoff limit started from the titer of 1:8.
378 Samples that did not show inhibitory activity or whose activity was below the 1:4
379 dilution were assigned the value of the 1:2 dilution, corresponding to the immediately
380 preceding dilution (15,16).

381 **Statistical analysis**

382 To outline the demographic characteristics of the study population, measures of
383 central tendency and dispersion were utilized for continuous variables, while
384 proportions were employed for discrete or categorical variables. Continuous
385 variables underwent analysis using one-way ANOVA and students' t-tests, whereas
386 non-parametric tests were applied to discrete variables.

387 For safety assessments, the z-test was employed to compare proportions between
388 treatment groups in the context of vaccine versus placebo, and the chi-square test
389 was used for comparisons involving administration routes, vaccine, or placebo.

390 Individual antibody titers were quantified as the highest dilution titer that elicited a
391 positive signal. Concurrently, the T-cell response was assessed by determining the
392 concentration of cytokine-producing cells after stimulation with the spike subunit 1
393 protein following an 18-hour incubation period. The population results were
394 characterized by a geometric mean (GM) and a 95% confidence interval.

395 **Results**

396 From November 23, 2022, to July 24, 2023, 1,221 volunteers underwent eligibility
397 assessments, and the distribution of recruited volunteers is depicted in Figure 1.
398 Various research sites across different states of Mexico participated in volunteer
399 recruitment, including Mexico City (Investigación en Salud (CAIMED), S. A. de C. V.,
400 Unidad de Medicina Familiar No. 20 IMSS, CEMDEC S.A de C.V., and Unidad
401 Clínica Farmacológica Bioemagno S.A. de C.V.) and Oaxaca (Oaxaca Site
402 Management Organization (OSMO) S.C.).

403 Of the 1,221 volunteers initially screened, 1,011 participants did not meet the
404 eligibility criteria during their first visit. The remaining 210 participants underwent
405 assessment against both inclusion and exclusion criteria. During the second visit, 52
406 participants were excluded for not meeting the eligibility and inclusion criteria as
407 described earlier. Therefore, the final cohort of participants comprised 158
408 individuals who were then randomized to receive either the AVX/COVID-12 vaccine
409 or a placebo. The administration routes included IM and IN (Figure 1A).

410 In the AVX/COVID-12 vaccine group, 41 participants received IM immunization,
411 while 40 received IN. Five participants from the IM group and four from the IN group
412 withdrew from the study, resulting in 36 participants in each analyzed subgroup. In
413 the placebo group, 40 participants were assigned to IM and 37 to IN administration.
414 Subsequently, participants from the placebo group (36 from the IM group and 35
415 from the IN group) were inoculated with the AZ/ChAdOx-1-S vaccine 14 days after
416 initially receiving the placebo; 7 participants from the IM group and six from the IN
417 group withdrew from the study. A total of 136 participants completed the study
418 (Figure 1B).

419 There were no statistically significant differences in age, gender, body mass index,
420 or comorbidities between the IM and IN vaccinated groups and their respective
421 placebo groups, except for race between the AVX/COVID-12 IM vaccinated group
422 and its placebo ($p=0.012$) (Table 1).

423 In Mexico, various vaccines, including adenoviral vectors (AstraZeneca, CanSino,
424 Johnson & Johnson, Sputnik V), inactivated viruses (Sinovac), and mRNA (Pfizer-
425 BioNTech), were employed for the national vaccination campaign. Therefore, an

426 additional inclusion criterion during the recruitment phase was completing the
427 primary vaccination series with any of the mentioned vaccines. A comparable
428 number of individuals with a similar history of prior vaccination were enrolled in each
429 group. No statistically significant differences were observed between the groups
430 regarding the history of previous SARS-CoV-2 vaccination, indicating a comparable
431 proportion of subjects vaccinated with various vaccine technologies (Table 2).

432 **Safety after vaccination with AVX/COVID-12**

433 AEs were documented in subjects receiving IM AVX/COVID-12 (n=41), IM placebo
434 (n=40), IN AVX/COVID-12 (n=40), and IN placebo (n=37) (total subjects 158). At day
435 28, IM and IN placebo group subjects received the AZ/ChAdOx-1-S vaccine, and
436 AEs were recorded (n=71). Therefore, AEs were documented for 158 subjects
437 receiving IM or IN AVX/COVID-12 vaccine and placebo groups, in addition to 71
438 subjects from the IM and IN placebo group who received the AZ/ChAdOx-1-S
439 vaccine, making a total of 229 subjects (Tables 1S).

440 From the 229 subjects analyzed, 186 subjects reported AEs, with 38 belonging to
441 the group that received the AVX/COVID-12 vaccine IM and 31 from the IM placebo
442 group. Furthermore, 36 individuals came from the group that received the
443 AVX/COVID-12 vaccine IN, and 29 subjects received the IN placebo. Considering
444 the number of subjects recruited for each group that received the vaccine IM
445 administration (vaccine or placebo), it was observed that 92.68% of participants who
446 received the AVX/COVID-12 vaccine reported AEs, while the percentage for the IM
447 placebo group was 77.5%. This difference in proportions for both groups was
448 statistically significant, with a higher proportion of affected subjects in the
449 AVX/COVID-12 vaccine group (Figure 2A). Analyzing the groups that received the
450 AVX/COVID-12 vaccine and placebo IN, it was observed that 90% and 78.37% of
451 subjects in these groups reported adverse events, respectively. The difference
452 between these proportions was not statistically significant (Figure 2A).

453 After completing the follow-up period and unblinding the study, subjects initially
454 receiving the placebo were administered a booster with the AZ/ChAdOx-1-S vaccine.
455 The proportion of subjects reporting any AEs in the group that received the
456 AVX/COVID-12 vaccine was significantly higher than the group that received the
457 AZ/ChAdOx-1-S vaccine (Figure 2A). No significant differences were observed in
458 the proportions of both groups when AEs were analyzed and grouped by severity.

459 Special interest local AEs reported at 7 days post-immunization, categorized by the
460 number of affected subjects, were recorded (Table 2S). About, 19.21% of the study
461 participants reported being affected by at least one of these events. Specifically, for
462 each study group, this corresponds to 41.46% for the AVX/COVID-12 IM group, 15%
463 for the IM placebo group, 17.5% for the AVX/COVID-12 IN group, 5.4% for the IN
464 placebo group, and 16.9% for the AZ/ChAdOx-1-S group. When comparing the
465 proportion of subjects affected by the total events (Table 2S), it was observed that
466 AVX/COVID-12 IM had a significantly higher proportion than IM placebo (p=0.008)

467 and AZ/ChAdOx-1S vaccine ($p=0.004$). This pattern was also observed for mild
468 events, while for moderate and severe events, no statistically significant differences
469 were found among these groups (Table 2S).

470 We identified statistically significant differences in AEs related to local general
471 disorders and administration site conditions when comparing the group receiving
472 AVX/COVID-12 IM with the AZ/ChAdOx-1-S vaccine group ($p=0.001$). Additionally,
473 when the AVX/COVID-12 vaccinated group was compared with the placebo group,
474 statistically significant differences were also observed ($p=0.003$) (Figure 2B).
475 General discomfort included symptoms such as injection site pain (Table 2S).

476 Similarly, we analyzed systemic AEs of special interest reported within 7 days after
477 the administration of the AVX/COVID-12 vaccine. About, 44.1% of the study
478 participants reported being affected by one of these events. Specifically, 58.53%
479 corresponded to the IM AVX/COVID-12 group, 50% to the IM placebo group, 57.5%
480 to the IN AVX/COVID-12 group, 40.54% to the IN placebo group, and 26.76% to the
481 AZ/ChAdOx-1-S group (Table 3S). When comparing groups, it was observed that
482 the group receiving IM AVX/COVID-12 had a significantly higher proportion of
483 subjects affected by this type of event than the AZ/ChAdOx-1-S group ($p=0.0009$).
484 Analyzing events according to severity, a significant difference was found for mild
485 events (Table 3S).

486 Subsequently, an analysis of events classified by system organ class (SOC) and
487 preferred term (PT) for systemic AEs at 7 days post-immunization was performed
488 (Table 3S). This analysis shows that the group receiving IM AVX/COVID-12 had a
489 significantly higher proportion of subjects affected than the AZ/ChAdOx-1-S group
490 for mild disorders of the nervous system, particularly headache ($p=0.006$); mild
491 gastrointestinal disorders, particularly odynophagia ($p=0.01$); and mild thoracic and
492 mediastinal respiratory disorders, particularly rhinorrhea ($p=0.0009$) (Figure 2C and
493 Table 3S).

494 In the comparison between IM AVX/COVID-12 and placebo, a statistically significant
495 difference was observed in the proportion of subjects affected by general disorders
496 and site administration alterations ($p=0.05$). When the AVX/COVID-12 vaccine was
497 administered IN, a significantly higher proportion of subjects showed mild
498 gastrointestinal disorders compared to the IN placebo group ($p=0.03$) (Figure 2C).

499 Finally, regarding AEs related to vaccination, 9.17% of subjects reported AEs (Table
500 4S). In particular, 14.63% of subjects in the IM AVX/COVID-12 group, 10% in the IM
501 placebo group, 7.5% in the IN AVX/COVID-12 group, 2.7% in the IN placebo group,
502 and 9.85% in the AZ/ChAdOx-1-S group were reported. When analyzing events by
503 SOC and PT, no statistically significant differences were observed despite variations
504 in the proportion of subjects affected (Figure 2D).

505 **AVX/COVID-12 induced binding and neutralizing antibody titers against**
506 **Wuhan-1 and SARS-CoV-2 variants of concern**

507 The evaluation of antibody titers and their neutralizing capacity in sera from
508 AVX/COVID-12 vaccinated volunteers against the spike protein was conducted
509 using ELISA and the pseudovirus neutralization assay at 14 days post-immunization,
510 both for the total number of volunteers vaccinated with AVX/COVID-12 IM and for
511 subjects who did not develop COVID-19 during the initial 14 days of the study (Table
512 3). Subsequent assessments were carried out over one year in IM-vaccinated
513 subjects (Table 5S and 6S) and IN (Table 7S and 8S).

514 The antibody response was analyzed for a year following immunization with the
515 AVX/COVID-12 vaccine via intramuscular and intranasal routes. Significant
516 differences are observed at all time points for anti-spike IgG antibodies in vaccinated
517 participants; titers increased at all analyzed time points compared to baseline levels
518 (Figure 3A), with the highest levels observed on day 14 post-immunization, followed
519 by a gradual decline. Interestingly, a slight increase is observed on day 365, possibly
520 due to SARS-CoV-2 infections during participants' follow-up. When analyzing the
521 population, excluding those who developed mild COVID-19 during the study period
522 (Figure 3B), a similar antibody kinetics was observed. Additionally, when analyzing
523 IgG anti-S titers in volunteers vaccinated IN, a comparable pattern is observed when
524 excluding subjects positive for COVID-19 (Figure 3B).

525 AVX/COVID-12 induced a ≥ 4 -fold increase in anti-spike IgG titers in 73.7% of the
526 subjects receiving IM immunization when compared to placebo (10%) ($p < 0.0001$).
527 In contrast, individuals receiving the vaccine IN showed a ≥ 4 -fold increase of 51.3%,
528 compared to 16.2% in the placebo group ($p = 0.001$) (Figure 4A). Similarly, 76.5% of
529 subjects who did not experience COVID-19 in the first 14 days post-immunization
530 and received IM AVX/COVID-12 showed a ≥ 4 -fold increase compared to 0% in the
531 placebo group ($p < 0.0001$). Meanwhile, 48.6% of volunteers who received the
532 vaccine IN exhibited a ≥ 4 -fold increase compared to 7.1% in the placebo group
533 ($p < 0.0001$) (Figure 4B).

534 Subsequently, neutralizing antibody titers against SARS-CoV-2 Wuhan-1 and Alpha,
535 Beta, Delta, and Omicron BA.2 and BA.5 VOCs were analyzed. For the IM-
536 administered AVX/COVID-12 vaccine, statistically significant differences in the
537 neutralizing antibody responses were observed when compared to the placebo in all
538 cases (Figure 5 and Table 5S). In contrast, in subjects who received IN immunization
539 with AVX/COVID-12, statistically significant differences in the neutralizing antibody
540 responses were only observed for Wuhan-1 and Alpha (Figure 5). In the case of
541 subjects who did not present COVID-19 in the first 14 days, all groups immunized
542 IM or IN showed statistically significant differences in the neutralizing antibody
543 responses when compared to the placebo group, except for the anti-BA.5
544 neutralizing responses in the IN immunized group (Figure 5 and Table 6S).

545 In addition, the proportion of subjects who exhibited a ≥ 2.5 -fold increase in
546 neutralizing antibody titers against Wuhan-1 and the aforementioned VOC was
547 determined. For subjects who received AVX/COVID-12 IM immunization, the

548 proportions of those exhibiting a ≥ 2.5 -fold increase in neutralizing antibody titers
549 range from 84.2% to 50% (Alpha > Wuhan-1 > Omicron BA.5 > Delta > Omicron
550 BA.2 > Beta), compared with subjects who received IM placebo, where 35.9% to
551 12.8% exhibited a ≥ 2.5 -fold increase in neutralizing antibody titers ($p < 0.0001$ to
552 0.003) (Figure 6A). For those vaccinated with AVX/COVID-12 IN, the percentage of
553 individuals who exhibited a ≥ 2.5 -fold increase in neutralizing antibody titers ranges
554 from 82.1% to 35.9% (Wuhan-1 > Alpha > Omicron BA.5 > Beta > Omicron BA.2 >
555 Delta) ($p > 0.0001$ to 0.045), except for the anti-BA.5 neutralizing antibody response,
556 where no statistically significant differences with the placebo were observed (Figure
557 6A).

558 In the sub-analysis, only subjects who did not present with COVID-19 in the first 14
559 days post-immunization were considered. For subjects who received AVX/COVID-
560 12 IM, the percentage of those exhibiting a ≥ 2.5 -fold increase in neutralizing
561 antibody titers ranged from 85.3% to 44.1% (Alpha > Wuhan-1 > Omicron BA.5 >
562 Delta > Omicron BA.2 > Beta), compared with volunteers administered a placebo,
563 ranging from 35.9% to 12.8% ($p > 0.0001$ to 0.03). Among the group vaccinated IN,
564 the percentage of individuals who exhibited a ≥ 2.5 -fold increase in neutralizing
565 antibody titers ranged from 81.1% to 32.4% (Wuhan-1 > Alpha > Omicron BA.5 >
566 Beta > Omicron BA.2 > Delta). However, except for of the anti-BA.5 neutralizing
567 antibody responses, no statistically significant difference was observed when
568 compared with the placebo group (Figure 6B). Nevertheless, it should also be noted
569 that the IN placebo control group presented an unusually higher rise of anti-BA.5
570 specific antibodies as compared to the other VOCs, perhaps indicative of a recent
571 infection.

572 **Comparable IFN- γ positive cellular responses were identified among**
573 **participants immunized with AVX/COVID-12, regardless of the administration**
574 **route**

575 IFN- γ production was measured from supernatants of PBMCs obtained from
576 volunteers vaccinated IM or IN (Tables 5 and 6) with the AVX/COVID-12 vaccine.
577 Cells were collected on days 0, 14, 180, and 365 (Table 7) and stimulated *in vitro*
578 with purified SARS-CoV-2 spike protein subunit 1 (Wuhan-1). In the total vaccinated
579 individuals, regardless of SARS-CoV-2 infection and/or COVID-19 confirmation
580 (SARS-CoV-2 PCR+/- and/or COVID-19+/-) (Table 7), statistically significant
581 differences in IFN- γ production were observed at day 365 for IM-vaccinated
582 individuals ($p < 0.01$) and at days 180 ($p < 0.03$) and 365 ($p < 0.01$) in IN-vaccinated
583 individuals (Figure 7A).

584 Meanwhile, in subjects who did not test positive for SARS-CoV-2 in a PCR test
585 and/or COVID-19 confirmation (SARS-CoV-2 PCR and/or COVID-19 negative)
586 (Table 8), the response observed at day 365 was higher compared to the SARS-
587 CoV-2 PCR+/- and/or COVID-19+/- group for both IM and IN immunized individuals.
588 A trend towards increased IFN- γ concentration was evident in both IM and IN

589 immunized groups with the AVX/COVID-12 vaccine; however, no statistically
590 significant differences were observed (Figure 7B).

591 **Immunization with the AVX/COVID-12 vaccine induces notably low specific** 592 **antibody titers against the NDV vector**

593 To assess the immune response elicited against the NDV vaccine vector, we
594 evaluated the specific antibody titers exhibiting hemagglutination inhibition (HAI)
595 activity in serum samples from individuals participating in phase I and II studies.

596 No antibodies with specific HAI against NDV were detected in all serum samples
597 from individuals who participated in the phase II study on day 0 of recruitment, before
598 the administration of the AVX/COVID-12 vaccine as a booster dose. Samples above
599 the cut-off threshold of 8 HAI titers were considered positive. On day 14 following
600 the initial administration of the AVX/COVID-12 vaccine, only two samples displayed
601 titers above 8, indicating seroconversion. Meanwhile, on days 42 and 90, 4 and 3
602 out of 144 sera exhibited titers equal to or greater than 8, respectively. These results
603 demonstrate that the administration of the AVX/COVID-12 vaccine at a dose of $10^{8.0}$
604 EID₅₀/dose via the IM route induces a low specific seroconversion to NDV (Figure
605 8).

606 In addition, serum samples from individuals participating in phase I, who received
607 two doses of $10^{8.0}$ EID₅₀/dose of the AVX/COVID-12 vaccine, were analyzed. It was
608 observed that all serum samples were negative for specific antibodies to the NDV
609 vector before the first immunization via IN or IM administration. On day 14 after
610 immunization, only 1 sample was positive. Meanwhile, titers higher than 8 were
611 detected after the second application of the AVX/COVID-12 vaccine (Day 42). On
612 the 90th day of follow-up, only 4 out of 10 sera showed titers higher than 8. After one
613 year, volunteers received a third dose as a boost. Before boosting, only 6 volunteers
614 had antibody titers equal to or greater than 8. After boosting, 42 out of 43 samples
615 were positive, most showing low titers against NDV. Seroconversion slowly faded,
616 and on day 90 after the boost, only 28 samples showed low antibody titers (Figure
617 8). Collectively, the data reveal that the induction of NDV-specific antibodies is
618 exceedingly low (less than 0.2%) in the studied population after a single dose of the
619 AVX/COVID-12 vaccine. Following the second and third immunizations,
620 seroconversion increased; nevertheless, antibody titers remained at a low level. It is
621 important to emphasize that the technique developed with highly sensitive.

622 **Discussion**

623 SARS-CoV-2 and its VOCs have had a staggering effect on human health
624 worldwide. Despite the development and rapid deployment of vaccines against
625 SARS-CoV-2, many countries, particularly low and middle-income countries, have
626 not yet met their vaccination needs. This underscores the urgency of establishing
627 vaccine development and production capabilities in these regions to contribute to a
628 quicker onset of global community immunity against severe disease.

629 The periodic administration of booster doses emerges as an essential measure to
630 sustain community immunity against severe disease, reducing the magnitude of
631 future waves of COVID-19 and safeguarding vulnerable populations, including the
632 elderly, immunocompromised individuals, and those with comorbidities (17).

633 In this phase II clinical trial, we assessed the safety and immunogenicity of the
634 AVX/COVID-12 vaccine as a booster dose in volunteers who had previously
635 received COVID-19 vaccines based on adenoviral technology, inactivated virus, or
636 mRNA technology and exhibited antibody titers lower than 1,200 U/mL. These titers
637 were considered sufficiently low to observe the booster effect induced by the IM or
638 IN administration of AVX/COVID-12. Recruitment presented particular challenges
639 due to the prevailing infections with Delta and Omicron variants (BA.1 to BA.5) in
640 Mexico at the time of the trial, resulting in a high prevalence of antibody titers in the
641 population (Figure 1S).

642 After screening 1,221 volunteers, we ultimately enrolled 158 subjects who met the
643 inclusion criteria (Figure 1). The IM or IN booster immunization with AVX/COVID-12
644 was safe and well-tolerated for all individuals analyzed; most of the AEs were mainly
645 mild, and fewer were of moderate extent (Figure 2A). The vaccine exhibited
646 appropriate tolerability, and its safety profile did not raise any concerns, irrespective
647 of the volunteers' initial vaccination history (Figure 2B-C). AEs potentially associated
648 with the vaccine were also mild and occurred in a small number of the volunteers
649 (Figure 2D). Additionally, the safety profile of AVX/COVID-12 was similar to that
650 observed for AZ/ChAdOx-1-S (Figure 2), the most widely used vaccine in Mexico
651 and worldwide (18,19).

652 We observed a substantial increase in spike binding (Figures 3 and 4) and
653 neutralizing antibody titers (Figure 5) among all volunteers following booster doses
654 of AVX/COVID-12 administered through IM and IN routes. Specific anti-spike IgG
655 slowly decayed during the following six months, but titers remained high and
656 increased one year after vaccination, perhaps due to viral exposure (Figure 3). As
657 described above, the trial was performed during a pandemic infection wave;
658 therefore, some volunteers were infected (no hospitalizations or deaths were
659 observed). The antibody titer increase held true irrespective of the volunteers' initial
660 vaccination history, involving vaccines based on adenoviral technology, inactivated
661 virus, or mRNA technology.

662 In the case of influenza vaccines, a ≥ 4 -fold increase in HAI titers is considered a
663 successful seroconversion (20), and neutralizing antibody titers have also been
664 correlated with protection for SARS-CoV-2 (21). Here, we observed a high proportion
665 of subjects who received the AVX/COVID-12 vaccine showing a ≥ 4 -fold increase in
666 anti-S IgG titers. As anticipated, the IM route of immunization proved to be more
667 efficient than the IN route in inducing serum antibody titers (Figure 4).

668 Real-world evidence indicates that first-generation vaccines, utilizing the spike
669 protein from the original Wuhan-1 strain, exhibit high effectiveness against the

670 severity of infection (intensive care unit (ICU) admission or death) caused by various
671 subvariants of Omicron. For instance, a full vaccination scheme with a booster from
672 Moderna shows 95% effectiveness, Pfizer demonstrates 95-100% (22,23), while
673 AstraZeneca or Janssen exhibits 85-90% effectiveness (23). Additionally, the mRNA
674 vaccine BNT162b2 has been reported to be 84.9% effective in preventing intensive
675 care unit admission for COVID-19 in children and 95% in adolescents (24). Other
676 studies indicate a 90.9% effectiveness of this vaccine against hospitalization and
677 death caused by the Omicron BA.1 and BA.2 variants of SARS-CoV-2, while the
678 AZ/ChAdOx-1-S vaccine showed 82.3% effectiveness (25). Moreover, COVID-19
679 vaccines available in Mexico have been reported to significantly reduce the risk of
680 severe disease during the Omicron wave in the country (26).

681 Our results are in concordance with these observations: AVX/COVID-12 induced
682 neutralizing antibody responses not only against the Wuhan-1 original strain but also
683 against the Alpha, Beta, Delta, and Omicron (BA.2 and BA.5) variants (Figure 5). It
684 was particularly surprising to observe a higher proportion of individuals with a ≥ 2.5
685 increase in neutralizing titers against the BA.5 compared to BA.2, despite
686 recruitment being performed during the BA.1-4 and BA.5 pandemic waves (Figure
687 1S). These responses might be explained by the generation of hybrid immunity
688 induced by the combination of infection and vaccination or vice versa (3,4). In
689 addition, a significant cross-reactive response of both antibodies and T cells
690 generated by infection or vaccination has been identified; in the case of hybrid
691 immunity, these cross-reactive responses are heightened and broadened (3,4,27–
692 29). These findings align with the description of a large set of conserved epitopes in
693 the spike protein for both humoral and cellular responses among SARS-CoV-2
694 Wuhan-1 and VOCs, as well as SARS-CoV, MERS-CoV, and seasonal
695 coronaviruses, and even within all those in the *Orthocoronavirinae* group (30).

696 Across all study groups, an increase in IFN- γ levels at later time points is observed,
697 suggesting a potential response to infections during the study (Figure 6). This
698 phenomenon could be explained by the development of hybrid immunity, where the
699 cellular response, through constant restimulations, may enhance both the magnitude
700 of effector capacity (cytotoxicity and cytokine production) and the long-term memory
701 response (31,32).

702 We observed a tendency toward a more pronounced IFN- γ response in individuals
703 who recovered from the infection (Figure 7). This response can be attributed to the
704 development of antigen-specific T cells and memory cells targeting viral antigens of
705 the virus, as the antigen-specific stimulation utilizes the spike protein of the virus.
706 We have found that these cells can persist in circulation despite decreasing antibody
707 titers. Our study shows lower antibody titers at 180 and 365 days compared to those
708 observed 14 days after the first immunization (Figures 3 and 7). This increase might
709 also be attributed to continuous, asymptomatic contact with SARS-CoV-2, implying
710 the observed re-stimulation at day 365 (Figures 3 and 7). It is crucial to note the
711 study's limitation in quantifying IFN- γ using BioPlex, which analyzes IFN- γ

712 production derived from PBMCs stimulated with the spike protein, including natural
713 killer cells (NK), CD4+ and CD8+ T cells, and monocytes.

714 A significant concern when using vector vaccines is the potential development of
715 immune responses against the vector that could hinder its use in further
716 immunizations. In this sense, it is essential to note that seroconversion against the
717 NDV vector was almost absent after one or two immunizations, and the three-dose
718 immunization scheme induced low and transient antibody titers (Figure 8). This
719 suggests that the AVX/COVID-12 vaccine could be used repeatedly without losing
720 efficacy.

721 **Conclusions**

722 The administration of the AVX/COVID-12 “Patria” vaccine as a booster dose, either
723 IM or IN, was deemed safe and well-tolerated. This resulted in the extension of
724 immune responses, not only against the Wuhan-1 original strain but also against
725 other VOCs. The vaccine effectively enhanced preexisting immune responses,
726 supporting its use for boosting vaccination programs to expand and sustain
727 community immunity against severe outcomes in the population. These compelling
728 findings strongly advocate incorporating AVX/COVID-12 as an additional booster
729 dose for the general population.

730 **Acknowledgments**

731 From CONAHCYT, we acknowledge María Elena Álvarez-Buylla Rocés and Delia
732 Aideé Orozco Hernández for their role as an inter-institutional liaison and overall
733 facilitation of proceedings, committee evaluations, sanitary setup, and follow-up of
734 trial design approvals, evaluations, and progress. We additionally acknowledge the
735 broader support from various teams within all the clinical research sites and iLS
736 Clinical Research S. C., particularly Gabriela Rosas, Daniela Castro, Claudia
737 Aguilar, Roman Jarosch, and Alejandro Arias. From Laboratorio Avi-Mex, S. A. de
738 C. V., we acknowledge the following people for their operative support: Bernardo
739 Lozano Alcántara, Alejandro Ruiz, Rosalba Rodríguez, Leticia Espinosa Gervasio,
740 Rodrigo Yebra Reyes, Vanessa Escamilla Jiménez, Jaime Becerra Jiménez, Lorena
741 Juárez Pedraza, Sandra Yuridia Ang Tinajero, Avelia Ariadna Cuevas Cifuentes,
742 Juan Pablo Robles Álvarez, Avirán Almazán Gutiérrez, Aurora Betsabé Gutiérrez
743 Balderas, Merlenne Rubio Díaz, and Guadalupe Aguilar Rafael. From INER, we
744 acknowledge the following people for their technical support: Liliana Figueroa
745 Hernández, Francisco Cruz Flores, Claudia Ivett Hernández Lázaro, María Angelica
746 Velázquez González, Jessica Romero Rodríguez, Dulce Cinthia Soriano
747 Hernández, Milton Nieto Ponce, Edgar Reyna, Itzel Corona, José E. Márquez,
748 Angelica Moncada, and Pablo Franco-Mendoza. We acknowledge Sean Whelan
749 from the Icahn School of Medicine at Mount Sinai. From Instituto Politécnico
750 Nacional, Escuela Nacional de Ciencias Biológicas, we acknowledge Sonia Mayra
751 Pérez Tapia, Alexis Gabriel Suárez Gómez, and Sandra Comparán Alarcón.

752 **Funding:**

753 The funding for the clinical study was provided by the National Council for
754 Humanities, Science and Technology (CONAHCYT, México), except for all the
755 production and vaccine product supply, which was funded solely by Laboratorio Avi-
756 Mex, S. A. de C. V. (Avimex). CONAHCYT did not participate in the trial design but
757 did evaluate it and approved the project through their National Committee for
758 Science, Technology and Innovation in Public Health. Funding was managed by
759 Avimex and used to pay for all laboratory tests, clinical sites, and clinical
760 professionals. CONAHCYT also facilitated the identification, purchase, and
761 importation of certain supplies and the communication with other entities of the
762 Federal Mexican Government to facilitate the study.

763 **Conflict of interest:**

764 The vaccine candidate administered in this study was developed by faculty members
765 at the Icahn School of Medicine at Mount Sinai including P.P., F.K., and A.G.-S.
766 Mount Sinai is seeking to commercialize this vaccine; therefore, the institution and
767 its faculty inventors could benefit financially. The Icahn School of Medicine at Mount
768 Sinai has filed patent applications relating to SARS-849 CoV-2 serological assays
769 (USA Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503, and
770 63/024,436) and NDV-based SARS-CoV-2 vaccines (USA Provisional Application
771 Number: 63/251,020) which list F.K. as co-inventor. A.G.-S. and P.P. are co-
772 inventors in the NDV-based SARS-CoV-2 vaccine patent application. Patent
773 applications were submitted by the Icahn School of Medicine at Mount Sinai. Mount
774 Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-
775 2 and another company, CastleVax, to commercialize SARS-CoV-2 vaccines. F.K.,
776 P.P., and A.G.-S. serve on the scientific advisory board of CastleVax and are listed
777 as co-founders of the company. F.K. has consulted for Merck, Seqirus, Curevac, and
778 Pfizer, and is currently consulting for Gritstone, Third Rock Ventures, GSK, and
779 Avimex. The F.K. laboratory has been collaborating with Pfizer on animal models of
780 SARS-CoV-2. C.L.-M. has consulted for AstraZeneca. The A.G.-S. laboratory has
781 received research support from GSK, Pfizer, Senhwa Biosciences, Kenall
782 Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills
783 Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC,
784 Model Medicines, Atea Pharma, Applied Biological Laboratories, and Merck. A.G.-
785 S. has consulting agreements for the following companies involving cash and/or
786 stock: Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda,
787 Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar,
788 CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer, and Prosetta.
789 A.G.-S. has been an invited speaker in meeting events organized by Seqirus,
790 Janssen, Abbott, and AstraZeneca. PP has a consulting agreement with Avimex.

791 Members of Avimex developed the live vaccine used in this study. Avimex filed
792 patent applications with Mount Sinai and CONAHCYT. M.T., D.S.-M., C.L.-M.,

793 H.E.C.-C., F.C.-P., G.P.D.L., and B.L.-D. are named as inventors on at least one of
794 those patent applications. The clinical study was entirely performed in Mexico, and
795 Mount Sinai had no role in it. The rest of the participants are employees of their
796 corresponding institutions and declare no competing interests.

797 **Ethical responsibilities:**

798 The protocol was approved by the ethics, research, and biosafety committees of
799 each clinical research site, National Committee for Science, Technology and
800 Innovation in Public Health of the National Council for Humanities, Science and
801 Technology (CONAHCYT), and also by the Federal Commission for the Protection
802 against Sanitary Risks (COFEPRIS, Mexico) as a regulatory agency.

803 **Protection of humans and animals:**

804 No animals were used in this study. The protocol was designed to comply with the
805 ethical principles of the Helsinki Declaration, Good Clinical Practices, and the
806 applicable Mexican law.

807 **Data sharing:**

808 The protocol was registered in the National Registry of Clinical Studies under
809 number RNEC2021-AVXSARSCoV2VAC002 and published under NCT05205746.
810 Individual de-identified participant data will not be shared beyond the limits permitted
811 by the informed consent and Mexican law. Specifically, this includes the sharing of
812 the study protocol, statistical analysis plan, informed consent form, and approved
813 clinical study report. Additionally, other de-identified data allowed under the informed
814 consent and Mexican law may be shared. The data will be made available
815 immediately upon publication and for 12 months thereafter. Access to the data will
816 be granted solely to investigators with methodologically sound proposals, subject to
817 authorization by an independent review committee and the ethics committees
818 involved in approving the protocol. If required by law, authorization from the Federal
819 Commission for the Protection against Sanitary Risks (COFEPRIS) in Mexico will
820 also be obtained. Any use of the data must strictly adhere to the authorized purposes
821 outlined during the approval process.

822 **Privacy rights and informed consent:**

823 Informed Consent formats were provided and signed by all participants under Good
824 Clinical Practices and Mexican law. Personal data is confidential, and subjects are
825 not identified personally. Their data was analyzed and duly de-identified.

826

827 **References**

- 828 1. COVID-19 cases | WHO COVID-19 dashboard [Internet]. [cited 2024 Jan
829 18]. Available from: <https://data.who.int/dashboards/covid19/cases?n=c>

- 830 2. Global Dashboard for Vaccine Equity - UNDP Data Futures Platform
831 [Internet]. [cited 2023 Jan 5]. Available from: [https://data.undp.org/vaccine-](https://data.undp.org/vaccine-equity/)
832 [equity/](https://data.undp.org/vaccine-equity/)
- 833 3. Crotty S. Hybrid immunity. *Science* (80-) [Internet]. 2021 Jun 25 [cited 2024
834 Jan 18];372(6549):1392–3. Available from:
835 <https://www.science.org/doi/10.1126/science.abj2258>
- 836 4. Lasrado N, Barouch DH. SARS-CoV-2 Hybrid Immunity: The Best of Both
837 Worlds. *J Infect Dis* [Internet]. 2023 Nov 11 [cited 2024 Jan
838 18];228(10):1311–3. Available from: <https://dx.doi.org/10.1093/infdis/jiad353>
- 839 5. Declaración de la OMS sobre la composición antigénica de las vacunas
840 contra la COVID-19 [Internet]. [cited 2024 Jan 16]. Available from:
841 [https://www.who.int/es/news/item/13-12-2023-statement-on-the-antigen-](https://www.who.int/es/news/item/13-12-2023-statement-on-the-antigen-composition-of-covid-19-vaccines)
842 [composition-of-covid-19-vaccines](https://www.who.int/es/news/item/13-12-2023-statement-on-the-antigen-composition-of-covid-19-vaccines)
- 843 6. Wichaidit M, Nopsopon T, Sunan K, Phutrakool P, Ruchikachorn P,
844 Wanvarie D, et al. Breakthrough infections, hospital admissions, and
845 mortality after major COVID-19 vaccination profiles: a prospective cohort
846 study. *Lancet Reg Heal - Southeast Asia* [Internet]. 2023 Jan 1 [cited 2024
847 Jan 18];8. Available from:
848 <http://www.thelancet.com/article/S2772368222001226/fulltext>
- 849 7. Boletín Epidemiológico Sistema Nacional de Vigilancia Epidemiológica
850 Sistema Único de Información 2023 | Secretaría de Salud | Gobierno |
851 gob.mx [Internet]. [cited 2024 Jan 18]. Available from:
852 [https://www.gob.mx/salud/documentos/boletinepidemiologico-sistema-](https://www.gob.mx/salud/documentos/boletinepidemiologico-sistema-nacional-de-vigilancia-epidemiologica-sistema-unico-de-informacion-261547)
853 [nacional-de-vigilancia-epidemiologica-sistema-unico-de-informacion-261547](https://www.gob.mx/salud/documentos/boletinepidemiologico-sistema-nacional-de-vigilancia-epidemiologica-sistema-unico-de-informacion-261547)
- 854 8. Seephetdee C, Buasri N, Bhukhai K, Srisanga K, Manopwisedjaroen S,
855 Lertjintanakit S, et al. Mice immunized with the vaccine candidate hexapro
856 spike produce neutralizing antibodies against sars-cov-2. *Vaccines*.
857 2021;9(5):1–9.
- 858 9. Hsieh CL, Goldsmith JA, Schaub JM, DiVenere AM, Kuo HC, Javanmardi K,
859 et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes.
860 *Science* [Internet]. 2020 Sep 1 [cited 2023 Nov 15];369(6510):1501–5.
861 Available from: <https://pubmed.ncbi.nlm.nih.gov/32703906/>
- 862 10. Lara-Puente JH, Carreño JM, Sun W, Suárez-Martínez A, Ramírez-Martínez
863 L, Quezada-Monroy F, et al. Safety and Immunogenicity of a Newcastle
864 Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-
865 12-HEXAPRO (Patria), in Pigs. *MBio* [Internet]. 2021 Oct 1 [cited 2023 Jan
866 5];12(5). Available from: <https://pubmed.ncbi.nlm.nih.gov/34544278/>
- 867 11. Sun W, Liu Y, Amanat F, González-Domínguez I, McCroskery S, Slamang
868 S, et al. A Newcastle disease virus expressing a stabilized spike protein of
869 SARS-CoV-2 induces protective immune responses. *Nat Commun* [Internet].
870 2021 Dec 1 [cited 2024 Jan 31];12(1). Available from:

- 871 <https://pubmed.ncbi.nlm.nih.gov/34707161/>
- 872 12. Ponce-de-León S, Torres M, Soto-Ramírez LE, Calva JJ, Santillán-Doherty
873 P, Carranza-Salazar DE, et al. Interim safety and immunogenicity results
874 from an NDV-based COVID-19 vaccine phase I trial in Mexico. *npj Vaccines*
875 [Internet]. 2023;8(1):67. Available from: [https://doi.org/10.1038/s41541-023-](https://doi.org/10.1038/s41541-023-00662-6)
876 [00662-6](https://doi.org/10.1038/s41541-023-00662-6)
- 877 13. Guidelines on clinical evaluation of vaccines: regulatory expectations, Annex
878 1 , TRS No 924 [Internet]. [cited 2023 Nov 15]. Available from:
879 [https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of-](https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of-vaccines-regulatory-expectations)
880 [vaccines-regulatory-expectations](https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of-vaccines-regulatory-expectations)
- 881 14. Sano K, Bhavsar D, Singh G, Floda D, Srivastava K, Gleason C, et al.
882 SARS-CoV-2 vaccination induces mucosal antibody responses in previously
883 infected individuals. *Nat Commun* 2022 131 [Internet]. 2022 Sep 1 [cited
884 2024 Jan 18];13(1):1–8. Available from:
885 <https://www.nature.com/articles/s41467-022-32389-8>
- 886 15. Morokutti A, Redlberger-Fritz M, Nakowitsch S, Krenn BM, Wressnigg N,
887 Jungbauer A, et al. Validation of the modified hemagglutination inhibition
888 assay (mHAI), a robust and sensitive serological test for analysis of influenza
889 virus-specific immune response. *J Clin Virol* [Internet]. 2013 Apr [cited 2024
890 Jan 29];56(4):323–30. Available from:
891 <https://pubmed.ncbi.nlm.nih.gov/23375739/>
- 892 16. Kaufmann L, Syedbasha M, Vogt D, Hollenstein Y, Hartmann J, Linnik JE, et
893 al. An Optimized Hemagglutination Inhibition (HI) Assay to Quantify
894 Influenza-specific Antibody Titers. *J Vis Exp* [Internet]. 2017 Dec 1 [cited
895 2024 Jan 29];2017(130):55833. Available from: </pmc/articles/PMC5755515/>
- 896 17. Omer SB, Yildirim I, Forman HP. Herd Immunity and Implications for SARS-
897 CoV-2 Control. *JAMA* [Internet]. 2020 Nov 24 [cited 2024 Jan
898 18];324(20):2095–6. Available from:
899 <https://jamanetwork.com/journals/jama/fullarticle/2772167>
- 900 18. Covid World Vaccination Tracker - The New York Times [Internet]. [cited
901 2023 Nov 15]. Available from:
902 [https://www.nytimes.com/interactive/2021/world/covid-vaccinations-](https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html)
903 [tracker.html](https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html)
- 904 19. COVID-19: dosis confirmadas de vacunas en México 2021 | Statista
905 [Internet]. [cited 2023 Nov 15]. Available from:
906 [https://es.statista.com/estadisticas/1207394/dosis-confirmadas-vacunas-](https://es.statista.com/estadisticas/1207394/dosis-confirmadas-vacunas-covid-mexico/)
907 [covid-mexico/](https://es.statista.com/estadisticas/1207394/dosis-confirmadas-vacunas-covid-mexico/)
- 908 20. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza
909 Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced
910 Protection. *J Infect Dis* [Internet]. 2011 Dec 15 [cited 2024 Jan
911 18];204(12):1879–85. Available from: <https://dx.doi.org/10.1093/infdis/jir661>

- 912 21. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et
913 al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine
914 efficacy clinical trial. *Science* (80-) [Internet]. 2022 Jan 7 [cited 2024 Jan
915 31];375(6576):43–50. Available from:
916 <https://www.science.org/doi/10.1126/science.abm3425>
- 917 22. Buchan SA, Chung H, Brown KA, Austin PC, Fell DB, Gubbay JB, et al.
918 Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta
919 Symptomatic Infection and Severe Outcomes. *JAMA Netw Open* [Internet].
920 2022 Sep 1 [cited 2024 Jan 31];5(9):e2232760–e2232760. Available from:
921 <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2796615>
- 922 23. Paul P, El-Naas A, Hamad O, Salameh MA, Mhaimed N, Laswi I, et al.
923 Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in
924 reducing infection, hospitalization, severity, and mortality compared to Delta
925 and other variants: A systematic review. *Hum Vaccin Immunother* [Internet].
926 2023 [cited 2024 Jan 31];19(1). Available from: [/pmc/articles/PMC10054360/](https://pubmed.ncbi.nlm.nih.gov/37111111/)
- 927 24. Wu Q, Tong J, Zhang B, Zhang D, Xu J, Shen Y, et al. Real-world
928 Effectiveness of BNT162b2 in Children and Adolescents. *medRxiv* [Internet].
929 2023 Jun 21 [cited 2024 Jan 18];2023.06.16.23291515. Available from:
930 <https://www.medrxiv.org/content/10.1101/2023.06.16.23291515v2>
- 931 25. Kirsebom FCM, Andrews N, Sachdeva R, Stowe J, Ramsay M, Lopez Bernal
932 J. Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the
933 Omicron and Delta variants in England. *Nat Commun* 2022 131 [Internet].
934 2022 Dec 12 [cited 2024 Jan 18];13(1):1–9. Available from:
935 <https://www.nature.com/articles/s41467-022-35168-7>
- 936 26. Hernández-Ávila M, Vieyra-Romero WI, Gutiérrez-Díaz H, Zepeda-Tello R,
937 Alpuche-Aranda C, Hernández-Ávila JE, et al. The Omicron wave in Mexico:
938 vaccine protection against progression to severe Covid-19 in SARS-CoV-2-
939 infected workers. *Salud Publica Mex* [Internet]. 2024 [cited 2024 Jan
940 18];66(1, ene-feb):85–94. Available from:
941 <https://www.saludpublica.mx/index.php/spm/article/view/15125>
- 942 27. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al.
943 SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and
944 uninfected controls. *Nat* 2020 5847821 [Internet]. 2020 Jul 15 [cited 2024
945 Jan 18];584(7821):457–62. Available from:
946 <https://www.nature.com/articles/s41586-020-2550-z>
- 947 28. Stamatatos L, Czartoski J, Wan YH, Homad LJ, Rubin V, Glantz H, et al.
948 mRNA vaccination boosts cross-variant neutralizing antibodies elicited by
949 SARS-CoV-2 infection. *Science* (80-) [Internet]. 2021 Jun 25 [cited 2024 Jan
950 18];372(6549):1413–8. Available from:
951 <https://www.science.org/doi/10.1126/science.abg9175>
- 952 29. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al.
953 Prior SARS-CoV-2 infection rescues B and T cell responses to variants after

- 954 first vaccine dose. *Science* (80-) [Internet]. 2021 Jun 25 [cited 2024 Jan
955 18];372(6549):1418–23. Available from:
956 <https://www.science.org/doi/10.1126/science.abh1282>
- 957 30. Singh G, Abbad A, Kleiner G, Srivastava K, Gleason C, Carreño JM, et al.
958 The post-COVID-19 population has a high prevalence of cross-reactive
959 antibodies to spikes from all Orthocoronavirinae genera. *MBio* [Internet].
960 2024 Jan 16 [cited 2024 Jan 19]; Available from:
961 <https://journals.asm.org/doi/10.1128/mbio.02250-23>
- 962 31. Jarjour NN, Masopust D, Jameson SC. T Cell Memory: Understanding
963 COVID-19. *Immunity* [Internet]. 2021 Jan 1 [cited 2023 Jul 11];54(1):14.
964 Available from: [/pmc/articles/PMC7749639/](https://pubmed.ncbi.nlm.nih.gov/34111111/)
- 965 32. Guerrera G, Picozza M, D’Orso S, Placido R, Pirronello M, Verdiani A, et al.
966 BNT162b2 vaccination induces durable SARS-CoV-2-specific T cells with a
967 stem cell memory phenotype. *Sci Immunol* [Internet]. 2023 Jul
968 12;6(66):eabl5344. Available from:
969 <https://doi.org/10.1126/sciimmunol.abl5344>
- 970
- 971




Figure 1. Screening and randomization of the participants. A) Flowchart depicting participant screening, randomization, and distribution across various experimental groups throughout the study. B) Scheme illustrating the distribution of volunteers into groups and post-boosting monitoring.




Figure 2. Adverse events 7 days after vaccination with AVX/COVID-12 or AZ/ChAdOx-1-S. Adverse events in participants following vaccination with the AVX/COVID-12 vaccine, compared with the AZ/ChAdOx-1-S vaccinated and placebo group. A) Percentage of participants affected by adverse events classified by severity; B) Local adverse events of special interest; C) Systemic adverse events of special interest; and D) Adverse events potentially associated with the vaccine. p-value calculated from a comparison of proportions (Z-test). Statistically significant differences were observed with p-values: $p \leq 0.05$.




Figure 3. Intramuscular and intranasal administration of the AVX/COVID-12 vaccine resulted in comparable anti-spike IgG antibody titers. Geometric means and confidence intervals of serum antibody titers post-vaccination with the AVX/COVID-12 vaccine were assessed A) intramuscularly (red circles) and intranasally (blue triangles) throughout the study and B) intramuscularly (red circles) and intranasally (blue triangles) in subjects where COVID-19 was not detected during the study follow-up period. P values were calculated by comparing the geometric means using the Wilcoxon signed-rank test with variables presented on a logarithmic scale.




Figure 4. Proportion of subjects with a ≥ 4 -fold increase in anti-spike IgG antibody titers. (A) All enrolled study participants and (B) subjects where SARS-CoV-2 infection was not detected during the 14 days after vaccination. P values were calculated using Fisher's exact test.




Figure 5. Comparison of neutralizing antibody titers against SARS-CoV-2 variants of concern (VOC) in subjects 14 days after receiving AVX/COVID-12 or placebo. Geometric mean comparison of neutralizing antibody titers against Wuhan, Delta, Alpha, Beta, and Omicron (BA.2 and BA.5) VOCs in volunteers after 14 days of receiving AVX/COVID-12 intramuscular (IM) (closed red circles) or IM

placebo (open red circles) and AVX/COVID-12 intranasal (IN) (closed blue triangles) or IN placebo (open blue triangles). Analysis was performed on the total of vaccinated individuals, regardless of SARS-CoV-2 infection confirmation (SARS-CoV-2 PCR+/-), or in subjects who did not test positive for SARS-CoV-2 in a PCR test (SARS-CoV-2 PCR Negatives). Mann–Whitney U test with variables presented on a natural logarithmic scale.




Figure 6. Proportion of subjects with a ≥ 2.5 -fold increase in neutralizing titers against SARS-CoV-2 variants of concern induced by AVX/COVID-12 immunization. Neutralizing antibody titers against Wuhan, Delta, Alpha, Beta, and Omicron (BA.2 and BA.5) variants of concern were measured 14 days after intramuscular (IM) (red closed bars) or intranasal (IN) (blue closed bars)

AVX/COVID-12 administration, and IM (striped red bars) or IN (striped blue bars) placebo administration. A) In the total of vaccinated individuals, regardless of SARS-CoV-2 infection confirmation (SARS-CoV-2 PCR +/-) or B) in subjects who did not test positive for SARS-CoV-2 in a PCR test (SARS-CoV-2 PCR Negatives). P values were calculated using Fisher's exact test.




Figure 7. Cellular responses induced by the AVX/COVID-12 Vaccine. IFN- γ production was measured from peripheral blood mononuclear cells (PBMCs) of volunteers immunized intramuscularly (IM) with red circles or intranasally (IN) with blue triangles using the AVX/COVID-12 vaccine at the indicated time points. Volunteers' PBMCs were stimulated for 18 hours with purified SARS-CoV-2 S1 protein (Wuhan-1), and IFN- γ production was measured from cell culture supernatants using BioPlex. A) In the total vaccinated individuals, regardless of SARS-CoV-2 infection and/or COVID-19 confirmation (SARS-CoV-2 PCR +/- and/or COVID-19 +/-), or B) in subjects who did not test positive for SARS-CoV-2 in a PCR test and/or COVID-19 confirmation (SARS-CoV-2 PCR and/or COVID-19 Negative). Significant differences were calculated with the Wilcoxon signed-rank test.





Figure 8. Immunization with the AVX/COVID-12 vaccine induces notably low specific antibody titers against the NDV vector. Analysis of hemagglutination inhibition antibody (HAI) titers specific to the Newcastle disease virus (NDV) vector in sera from individuals who received the AVX/COVID-12 vaccine as a booster dose in the phase II clinical trial (green circles, n=154) or as part of the primary immunization scheme with two doses on day 0 and a booster on day 21 (orange circles, n=10), and after a homologous booster dose on day 365 in the phase I clinical trial (red circles, n=43). Samples above the cut-off threshold of 8 HAI titers were considered positive (dotted line).



Supplementary Figure 1. COVID-19 incidence in Mexico during the recruitment and monitoring of the study participants.

Tables

Table 1. Demographic characteristics of phase II study volunteers.

| | IM AVX | IM PL | p-Value | IN AVX | IN PL | p-Value |
|---------------------------------------|-------------|-------------|---------|-------------|-------------|---------|
| Volunteers (n) | 41 | 40 | | 40 | 37 | |
| Age, mean (SD) | 39.8 (11.9) | 33.5 (11.3) | 0.01 | 37.8 (13.5) | 36.6 (13.8) | 0.65 |
| Age groups (years old) | | | | | | |
| < 20 | - | - | 0.15 | 1 (2.5) | 1 (2.7) | 0.79 |
| 20 - 29 | 12 (29.27) | 22 (55) | | 11 (27.5) | 14 (37.84) | |
| 30 - 39 | 7 (17.07) | 6 (15) | | 12 (30) | 8 (21.62) | |
| 40 - 49 | 16 (39.02) | 7 (17.5) | | 6 (15) | 7 (18.92) | |
| 50 - 59 | 3 (7.32) | 3 (7.5) | | 7 (17.5) | 4 (10.81) | |
| 60 - 69 | 3 (7.32) | 2 (5) | | 3 (7.5) | 2 (5.41) | |
| 70 - 79 | - | - | | - | 1 (2.7) | |
| Gender, n (%) | | | | | | |
| Female | 21 (51.22) | 23 (57.5) | 0.57 | 19 (47.5) | 16 (43.24) | 0.70 |
| Male | 20 (48.78) | 17 (42.5) | | 21 (52.5) | 21 (56.76) | |
| MBI, mean (SD) | 26.3 (6.0) | 26.5 (5.1) | 0.43 | 26.7 (6.1) | 26.5 | 0.88 |
| BMI classification | | | | | | |
| Underweight | 2 (4.88) | 1 (2.5) | 0.68 | 3 (7.5) | 2 (5.41) | 0.64 |
| Normal | 11 (26.83) | 15 (37.5) | | 14 (35) | 14 (37.84) | |
| Overweight | 18 (43.9) | 17 (42.5) | | 10 (25) | 13 (35.14) | |
| Obesity | 10 (24.39) | 7 (17.5) | | 13 (32.5) | 8 (21.62) | |
| Race, n (%) | | | | | | |
| White | 3 (7.32) | 2 (5) | 0.012 | 1 (2.5) | 2 (5.41) | 0.14 |
| Amerindian | 10 (24.39) | 2 (5) | | 10 (25) | 3 (8.11) | |
| Mexican Mestizo | 27 (65.85) | 28 (70) | | 26 (65) | 31 (83.78) | |
| Other | 1 (2.44) | 8 (20) | | 3 (7.5) | 1 (2.7) | |
| Comorbidities, n (%) | | | | | | |
| 0 | 38 (92.68) | 39 (97.5) | 0.31 | 37 (92.5) | 33 (89) | 0.59 |
| 1 | 3 (7.32) | 1 (2.5) | 0.34 | 3 (7.5) | 4 (10) | 0.69 |
| Systolic arterial hypertension | 2 (4.87) | 1 (2.5) | 0.57 | 2 (5) | 2 (5) | 1 |
| Type 2 Diabetes Mellitus | - | - | | 1 (2.5) | - | NA |
| HIV | 1 (2.44) | - | NA | - | 2 (5) | NA |

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; SD: Standard Deviation; BMI: Body Mass Index. Mann–Whitney’s U test was conducted for median comparisons, and the Chi-Square test was used for categorical variables.

Table 2. Prior history of SARS-CoV-2 vaccination among phase II participants at baseline.

| | IM AVX | IM PL | p-Value | IN AVX | IN PL | p-Value |
|--|------------|-----------|---------|-----------|------------|---------|
| Volunteers (n) | 41 | 40 | | 40 | 37 | |
| Last vaccination schedule prior to the study, n (%) | | | | | | |
| Adenoviral Vector | 31 (75.6) | 33 (82.5) | 0.44 | 31 (77.5) | 33 (89.2) | 0.17 |
| AstraZeneca | 16 (39.02) | 16 (40) | 0.92 | 12 (30) | 14 (37.84) | 0.46 |

| | | | | | | |
|----------------------------|------------|-----------|------|-----------|------------|------|
| CanSino | 4 (9.76) | 4 (10) | 0.97 | 5 (12.5) | 8 (21.62) | 0.28 |
| Johnson & Johnson | 1 (2.44) | - | N/A | 1 (2.5) | - | N/A |
| Sputnik V | 10 (24.39) | 13 (32.5) | 0.41 | 13 (32.5) | 11 (29.73) | 0.79 |
| Inactivated Viruses | | | | | | |
| Sinovac | 6 (14.63) | 4 (10) | 0.52 | 5 (12.5) | 3 (8.11) | 0.52 |
| mRNA | | | | | | |
| Pfizer | 4 (9.76) | 3 (7.5) | 0.71 | 4 (10) | 1 (2.7) | 0.19 |

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; SD: Standard Deviation; BMI: Body Mass Index. Mann–Whitney’s U test was used for median comparisons, and the Chi-Square test was used for categorical variables.

Table 3. Proportion of subjects with an increase in neutralizing antibody titers against SARS-CoV-2 variants of concern 14 days after receiving AVX/COVID-12 or placebo.

| | All volunteers | | | | | |
|---|-----------------------|--------------|----------------|---------------|--------------|----------------|
| | IM AVX | IM PL | Valor p | IN AVX | IN PL | Valor p |
| Subjects per group: | 38 | 39 | | 39 | 37 | |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Wuhan-1 | 30 | 7 | | 32 | 9 | |
| Proportion | 78.9% | 17.9% | <0.0001 | 82.1% | 24.3% | <0.0001 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Delta | 21 | 7 | | 14 | 6 | |
| Proportion | 55.3% | 17.9% | 0.001 | 35.9% | 16.2% | 0.045 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Alpha | 32 | 10 | | 30 | 11 | |
| Proportion | 84.2% | 25.6% | <0.0001 | 76.9% | 29.7% | <0.0001 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Beta | 19 | 7 | | 19 | 8 | |
| Proportion | 50.0% | 17.9% | 0.003 | 48.7% | 21.6% | 0.012 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Omicron (BA.2) | 19 | 5 | | 16 | 6 | |
| Proportion | 50.0% | 12.8% | <0.0001 | 42.1% | 16.2% | 0.013 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Omicron (BA.5) | 27 | 14 | | 25 | 18 | |
| Proportion | 71.1% | 35.9% | 0.002 | 65.8% | 48.6% | 0.102 |
| Participants with a negative SARS-CoV-2 PCR test in the initial 14 days. | | | | | | |
| | IM AVX | IM PL | Valor p | IN AVX | IN PL | Valor p |
| Subjects per group: | 34 | 29 | | 37 | 28 | |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Wuhan-1 | 26 | 3 | | 30 | 6 | |
| Proportion | 76.5% | 10.3% | <0.0001 | 81.1% | 21.4% | <0.0001 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Delta | 18 | 4 | | 12 | 2 | |
| Proportion | 52.9% | 13.8% | <0.0001 | 32.4% | 7.1% | 0.013 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against Alpha | 29 | 6 | | 29 | 8 | |
| Proportion | 85.3% | 20.7% | <0.0001 | 78.4% | 28.6% | <0.0001 |
| Number of subjects with a ≥ 2.5 -fold | 15 | 3 | | 17 | 2 | |

| | | | | | | |
|---|-------|-------|---------|-------|-------|---------|
| increase in neutralizing titers against Beta | | | | | | |
| Proportion | 44.1% | 10.3% | 0.003 | 45.9% | 7.1% | 0.001 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against BA.2 | 17 | 0 | | 14 | 1 | |
| Proportion | 50.0% | 0.0% | <0.0001 | 38.9% | 3.6% | <0.0001 |
| Number of subjects with a ≥ 2.5 -fold increase in neutralizing titers against BA.5 | 25 | 8 | | 23 | 14 | |
| Proportion | 73.5% | 27.6% | <0.0001 | 63.9% | 50.0% | 0.195 |

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; P values are derived from Fisher's exact test.

Table 4. Proportion of subjects with an increase in neutralizing antibody titers at 14 days post-immunization against different variants of SARS-CoV-2.

| | IM AVX | IM PL | p-Value | IN AVX | IN PL | p-Value |
|---|--------|-------|---------|--------|-------|---------|
| Subjects per group | 38 | 39 | | 39 | 37 | |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against Wuhan-1 variant | 30 | 7 | | 32 | 9 | |
| Proportion | 78.9% | 17.9% | <0.0001 | 82.1% | 24.3% | <0.0001 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against Delta variant | 21 | 7 | | 14 | 6 | |
| Proportion | 55.3% | 17.9% | 0.001 | 35.9% | 16.2% | 0.045 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against Alpha variant | 32 | 10 | | 30 | 11 | |
| Proportion | 84.2% | 25.6% | <0.0001 | 76.9% | 29.7% | <0.0001 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against Beta variant | 19 | 7 | | 19 | 8 | |
| Proportion | 50.0% | 17.9% | 0.003 | 48.7% | 21.6% | 0.012 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against BA.2 | 19 | 5 | | 16 | 6 | |
| Proportion | 50.0% | 12.8% | <0.0001 | 42.1% | 16.2% | 0.013 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against BA.5 | 27 | 14 | | 25 | 18 | |
| Proportion | 71.1% | 35.9% | 0.002 | 65.8% | 48.6% | 0.102 |
| Subjects without COVID-19 in the first 14 days | | | | | | |
| | IM AVX | IM PL | p-Value | IN AVX | IN PL | p-Value |
| Subjects per group | 34 | 29 | | 37 | 28 | |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against Wuhan-1 variant | 26 | 3 | | 30 | 6 | |
| Proportion | 76.5% | 10.3% | <0.0001 | 81.1% | 21.4% | <0.0001 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against Delta variant | 18 | 4 | | 12 | 2 | |
| Proportion | 52.9% | 13.8% | <0.0001 | 32.4% | 7.1% | 0.013 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against Alpha variant | 29 | 6 | | 29 | 8 | |
| Proportion | 85.3% | 20.7% | <0.0001 | 78.4% | 28.6% | <0.0001 |

| | | | | | | |
|--|-------|-------|---------|-------|-------|---------|
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against Beta variant | 15 | 3 | | 17 | 2 | |
| Proportion | 44.1% | 10.3% | 0.003 | 45.9% | 7.1% | 0.001 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against BA.2 | 17 | 0 | | 14 | 1 | |
| Proportion | 50.0% | 0.0% | <0.0001 | 38.9% | 3.6% | <0.0001 |
| Number of subjects with ≥ 2.5 -fold increase in neutralizing antibody titers against BA.5 | 25 | 8 | | 23 | 14 | |
| Proportion | 73.5% | 27.6% | <0.0001 | 63.9% | 50.0% | 0.195 |

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; P values are derived from Fisher's exact test.

Table 5. IFN- γ secreted (pg/mL) by T lymphocytes, comparison on day 14 between AVX/COVID-12 and placebo.

| All volunteers | | | | | | |
|---|---------------|---------------|---------|------------|-------------|---------|
| | IM AVX | IM PL | p-Value | IN AVX | IN PL | p-Value |
| Subjects | 20 | 35 | | 20 | 33 | |
| GM | 324.2 | 258.6 | | 193.7 | 406.7 | |
| CI | 166.5 - 631.4 | 123.1 - 543.2 | 0.97 | 73 - 513.4 | 262 - 631.4 | 0.31 |
| Volunteers without COVID-19 in the first 14 days. | | | | | | |
| | IM AVX | IM PL | p-Value | IN AVX | IN PL | p-Value |
| Subjects | 17 | 27 | | 19 | 27 | |
| GM | 280 | 168.6 | | 175.5 | 358 | |
| CI | 133.3 - 588.1 | 71.2 - 399.2 | 0.71 | 64 - 481 | 220 - 581 | 0.33 |

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; GM: geometric mean; CI: confidence interval. Comparisons of GM at day 14 between groups, p values were calculated using the Mann-Whitney's U test.

Table 6. Proportion of subjects with an increase in IFN- γ secretion by peripheral blood T lymphocytes in response to stimulation with the S protein of SARS-CoV-2.

| All volunteers | | | | | | |
|---|--------|-------|---------|--------|-------|---------|
| | IM AVX | IM PL | p-Value | IN AVX | IN PL | p-Value |
| Subjects | 19 | 35 | | 17 | 32 | |
| Number of subjects with an increase ≥ 1.25 in interferon-gamma-producing T lymphocytes | 8 | 19 | | 7 | 20 | |
| Proportion | 42.1% | 54.3% | 0.569 | 41.1% | 62.5% | 0.228 |
| Volunteers without COVID-19 in the first 14 days. | | | | | | |
| | IM AVX | IM PL | p-Value | IN AVX | IN PL | p-Value |
| Subjects | 16 | 27 | | 16 | 26 | |

| | | | | | | |
|---|-------|-------|-------|-------|-------|-------|
| Number of subjects with an increase ≥ 1.25 in interferon-gamma-producing T lymphocytes | 7 | 15 | 7 | 18 | | |
| Proportion | 43.7% | 55.6% | 0.537 | 43.7% | 69.2% | 0.121 |

AVX: AVX/COVID-12; PL: placebo; IM: intramuscular; IN: intranasal; p-values were calculated using the Fisher's exact test.

Table 7. IFN- γ secreted (pg/mL) by T lymphocytes in subjects vaccinated with AVX/COVID-12 throughout the study.

| All volunteers | | | | |
|----------------|----------------|---------------|----------------|----------------|
| AVX IM | | | | |
| | Baseline | Day 14 | Day 180 | Day 365 |
| Subjects | 24 | 20 | 39 | 21 |
| GM | 235.8 | 324.2 | 867.1 | 1160.1 |
| CI | 107.1 - 519.2 | 166.5 - 631.4 | 602 - 1249.1 | 746- 1804.1 |
| p-Value | | 0.99 | 0.09 | 0.01 |
| AVX IN | | | | |
| | Baseline | Day 14 | Day 180 | Day 365 |
| Subjects | 20 | 20 | 34 | 18 |
| GM | 241.4 | 193.7 | 951.2 | 1011.3 |
| CI | 81.75248 713.1 | 73 - 513.4 | 648.5 - 1395.3 | 642.2 - 1592.4 |
| p-Value | | 0.83 | 0.03 | 0.01 |

AVX: AVX/COVID-12; IM: intramuscular; IN: intranasal; GM: geometric mean; CI: confidence interval. Comparison of GM using the Wilcoxon signed-rank test.

Table 8. IFN- γ secreted (pg/mL) by T lymphocytes in subjects without COVID-19 vaccinated with AVX/COVID-12 throughout the study.

| Volunteers without COVID-19 | | | |
|-----------------------------|----------------|----------------|----------------|
| AVX IM | | | |
| | Día 14 | Día 180 | Día 365 |
| Subjects | 3 | 24 | 17 |
| GM | 744.6 | 842.6 | 974 |
| CI | 40.4 - 13715.6 | 496.9 - 1428.9 | 583.9 - 1624.7 |
| AVX IN | | | |
| | Día 14 | Día 180 | Día 365 |
| Subjects | 19 | 18 | 8 |
| GM | 175.5 | 895.7 | 1374.6 |
| CI | 64 - 481 | 493.1 - 1626.9 | 614.3 - 3075.7 |

AVX: AVX/COVID-12; IM: intramuscular; IN: intranasal; GM: geometric mean; CI: confidence interval.

Table 1S. Proportion of affected subject by adverse events at 7 days post-immunization.

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX- PL p- value | IN AVX- PL p- value | AVX- AZ p- value |
|---|-------|-----------|---------|-------|--------|-----------|-------|-------|---------|-------|---------|-------|---------|---------------------------------|---------------------------------|---------------------------|
| Subjects | | 41 | | 40 | | 40 | | 37 | | 71 | | 229 | | | | |
| Any AE | Total | 38 | (92.68) | 31 | (77.5) | 36 | (90) | 29 | (78.37) | 52 | (73.23) | 186 | (81.22) | 0.05 | 0.16 | 0.01 |
| | MI | 38 | (92.68) | 31 | (77.5) | 36 | (90) | 29 | (78.37) | 51 | (71.83) | 185 | (80.78) | 0.05 | 0.16 | 0.008 |
| | Mo | 13 | (31.7) | 1 | (2.5) | 10 | (25) | 10 | (27.02) | 18 | (25.35) | 52 | (22.7) | 0.0005 | 0.83 | 0.46 |
| | S | 3 | (7.31) | 0 | (0) | 1 | (2.5) | 0 | (0) | 2 | (2.81) | 6 | (2.62) | 0.08 | 0.33 | 0.26 |
| Pregnancy, puerperium, and perinatal diseases | Total | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Abortion | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Pregnancy | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Supplementary examinations | Total | 4 | (9.75) | 0 | (0) | 2 | (5) | 1 | (2.7) | 0 | (0) | 7 | (3.05) | 0.04 | 0.60 | 0.007 |
| | Mi | 4 | (9.75) | 0 | (0) | 2 | (5) | 1 | (2.7) | 0 | (0) | 7 | (3.05) | 0.04 | 0.60 | 0.007 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Decrease in Glomerular Filtration Rate | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Elevation of Aspartate Aminotransferase | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Elevation of Cystatin C | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Elevation of Human Chorionic Gonadotropin | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Elevation of Lactate Dehydrogenase | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Elevation of Blood Pressure | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| Elevation of Systolic Pressure | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Elevation of Alanine Aminotransferase | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|--|--------------|--------|---------|-------|--------|--------|--------|-------|---------|-------|---------|-------|---------|-------------------|-------------------|----------------|
| Infections and infestations | Total | 36 | (87.8) | 15 | (37.5) | 29 | (72.5) | 13 | (35.13) | 37 | (52.11) | 130 | (56.76) | 0.0000 | 0.001 | 0.0001 |
| | Mi | 35 | (85.36) | 15 | (37.5) | 28 | (70) | 13 | (35.13) | 32 | (45.07) | 123 | (53.71) | 0.0000 | 0.002 | 0.0000 |
| | Mo | 4 | (9.75) | 0 | (0) | 5 | (12.5) | 2 | (5.4) | 7 | (9.85) | 18 | (7.86) | 0.04 | 0.27 | 0.98 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Dental Abscess | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Bronchitis | Mi | 2 | (4.87) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 4 | (1.74) | 0.15 | 0.33 | 0.27 |
| COVID-19 | Mi | 26 | (63.41) | 9 | (22.5) | 18 | (45) | 11 | (29.72) | 19 | (26.76) | 83 | (36.24) | 0.0002 | 0.16 | 0.0001 |
| COVID-19 | Mo | 1 | (2.43) | 0 | (0) | 3 | (7.5) | 0 | (0) | 1 | (1.4) | 5 | (2.18) | 0.32 | 0.08 | 0.69 |
| Toothache | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | 0.32 | 0.29 | 0.18 |
| Gastroenteritis | Mi | 0 | (0) | 0 | (0) | 3 | (7.5) | 1 | (2.7) | 2 | (2.81) | 6 | (2.62) | | 0.34 | 0.27 |
| | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | | 0.95 | |
| Gingivitis | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Hepatitis A | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Herpes Zoster | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | 0.44 |
| Bacterial Infection of Respiratory Tract | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| Respiratory Tract Infection | Mi | 9 | (21.95) | 0 | (0) | 5 | (12.5) | 0 | (0) | 4 | (5.63) | 18 | (7.86) | 0.001 | 0.02 | 0.009 |
| Upper Respiratory Tract Infection | Mi | 5 | (12.19) | 4 | (10) | 4 | (10) | 0 | (0) | 11 | (15.49) | 24 | (10.48) | 0.75 | 0.04 | 0.63 |
| Upper Respiratory Tract Infection | Mo | 2 | (4.87) | 0 | (0) | 2 | (5) | 1 | (2.7) | 3 | (4.22) | 8 | (3.49) | 0.15 | 0.60 | 0.87 |
| Urinary Tract Infection | Mo | 1 | (2.43) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.32 | 0.33 | 0.18 |
| Urinary Tract Infection | Mi | 1 | (2.43) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.32 | 0.33 | 0.18 |
| Dental Infection | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Dental Infection | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Vaginal Infection | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Influenza | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Pharyngitis | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Onychomycosis | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (2.81) | 2 | (0.87) | | | 0.27 |
| Osteomyelitis | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|---|--------------|--------|--------|-------|-------|--------|-------|-------|-------|-------|--------|-------|--------|-------------------|-------------------|----------------|
| Acute Otitis Media | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Acute Otitis Media | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Rhinitis | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| Rhinitis | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Post-Acute COVID-19 Syndrome | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| American Trypanosomiasis | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Bacterial Vaginosis | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Benign, Malignant, and Unspecified Neoplasms (Cysts and Polyps) | Total | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Lipoma | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Traumatic injuries, poisonings, and complications of therapeutic procedures | Total | 3 | (7.31) | 4 | (10) | 3 | (7.5) | 1 | (2.7) | 5 | (7.04) | 16 | (6.98) | 0.66 | 0.34 | 0.99 |
| | Mi | 2 | (4.87) | 4 | (10) | 3 | (7.5) | 1 | (2.7) | 4 | (5.63) | 14 | (6.11) | 0.37 | 0.34 | 0.86 |
| | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Epicondylitis | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Dental Fracture | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| Sunstroke | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Injury | Mi | 2 | (4.87) | 1 | (2.5) | 2 | (5) | 1 | (2.7) | 0 | (0) | 6 | (2.62) | 0.57 | 0.60 | 0.06 |
| Traumatic Skin Injury | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Facial Traumatic Injury | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Animal Bite | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Chemical Burn | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Chemical Burn | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Thermal Burn | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|--|--------------|----------|---------------|----------|---------------|----------|--------------|----------|--------------|----------|----------------|-----------|---------------|-------------------|-------------------|----------------|
| Injection-Related Reaction | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| Medical and Surgical Procedures | Total | 1 | (2.43) | 0 | (0) | 3 | (7.5) | 0 | (0) | 3 | (4.22) | 7 | (3.05) | 0.32 | 0.08 | 0.62 |
| | Mi | 1 | (2.43) | 0 | (0) | 3 | (7.5) | 0 | (0) | 3 | (4.22) | 7 | (3.05) | 0.32 | 0.08 | 0.62 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Dental Care | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Periodontal Surgery | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Tooth Extraction | Mi | 0 | (0) | 0 | (0) | 2 | (5) | 0 | (0) | 1 | (1.4) | 3 | (1.31) | | 0.16 | 0.44 |
| Hysterectomy | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Removal of Intrauterine Contraceptive Device | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Cardiac Disorders | Total | 0 | (0) | 0 | (0) | 1 | (2.5) | 1 | (2.7) | 2 | (2.81) | 4 | (1.74) | | 0.95 | 0.27 |
| | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | | 0.95 | |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (2.81) | 2 | (0.87) | | | 0.27 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Arrhythmia | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Chest Pain | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Palpitations | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Tachycardia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| Skin and Subcutaneous Tissue Disorders | Total | 0 | (0) | 5 | (12.5) | 3 | (7.5) | 0 | (0) | 8 | (11.26) | 16 | (6.98) | 0.01 | 0.08 | 0.03 |
| | Mi | 0 | (0) | 5 | (12.5) | 3 | (7.5) | 0 | (0) | 7 | (9.85) | 15 | (6.55) | 0.01 | 0.08 | 0.04 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Acne | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Dermatitis | Mi | 0 | (0) | 2 | (5) | 2 | (5) | 0 | (0) | 2 | (2.81) | 6 | (2.62) | 0.14 | 0.16 | 0.27 |
| Dermatitis | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Bruising | Mi | 0 | (0) | 1 | (2.5) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.30 | 0.33 | |
| Erythema | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |

| SOC | PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|-----|---|--------------|----------|----------------|----------|--------------|----------|--------------|----------|--------------|----------|---------------|-----------|---------------|-------------------|-------------------|----------------|
| | Granuloma | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| | Hyperhidrosis | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | Petechiae | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| | Pruritus | Mi | 0 | (0) | 1 | (2.5) | 1 | (2.5) | 0 | (0) | 2 | (2.81) | 4 | (1.74) | 0.30 | 0.33 | 0.27 |
| | Disorders of the blood and lymphatic system | Total | 2 | (4.87) | 3 | (7.5) | 3 | (7.5) | 3 | (8.1) | 0 | (0) | 11 | (4.8) | 0.62 | 0.92 | 0.06 |
| | | Mi | 2 | (4.87) | 3 | (7.5) | 3 | (7.5) | 2 | (5.4) | 0 | (0) | 10 | (4.36) | 0.62 | 0.70 | 0.06 |
| | | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| | | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | Hypochromic anemia | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | Basophilia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| | Coagulopathy | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| | Eosinophilia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| | Leucopenia | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | Lymphopenia | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | Neutrophilia | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| | Neutropenia | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | | 0.95 | |
| | Thrombocytosis | Mi | 2 | (4.87) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 0 | (0) | 4 | (1.74) | 0.57 | 0.29 | 0.06 |
| | Thrombocytopenia | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| | Reproductive and breast disorders | Total | 5 | (12.19) | 2 | (5) | 1 | (2.5) | 3 | (8.1) | 7 | (9.85) | 18 | (7.86) | 0.24 | 0.26 | 0.70 |
| | | Mi | 3 | (7.31) | 2 | (5) | 1 | (2.5) | 1 | (2.7) | 6 | (8.45) | 13 | (5.67) | 0.66 | 0.95 | 0.83 |
| | | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 2 | (5.4) | 2 | (2.81) | 5 | (2.18) | 0.32 | 0.13 | 0.90 |
| | | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | Dysmenorrhea | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 1 | (1.4) | 3 | (1.31) | 0.30 | 0.29 | 0.44 |
| | Dysmenorrhea | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| | Vaginal bleeding | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | Polycystic ovaries | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| | Breast cyst | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|--|--------------|-----------|----------------|----------|---------------|----------|-------------|----------|----------------|----------|--------------|-----------|---------------|-------------------|-------------------|----------------|
| Prostatitis | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Delayed menstruation | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Heavy menstrual bleeding | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Menstrual disorders | Mi | 1 | (2.43) | 1 | (2.5) | 0 | (0) | 0 | (0) | 3 | (4.22) | 5 | (2.18) | 0.98 | | 0.62 |
| Menstrual disorders | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 1 | (1.4) | 2 | (0.87) | | 0.29 | 0.44 |
| Ovarian cyst | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Varicocele | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Metabolic and Nutritional Disorders | Total | 10 | (24.39) | 7 | (17.5) | 6 | (15) | 6 | (16.21) | 1 | (1.4) | 30 | (13.1) | 0.44 | 0.88 | 0.001 |
| | Mi | 10 | (24.39) | 7 | (17.5) | 6 | (15) | 6 | (16.21) | 1 | (1.4) | 30 | (13.1) | 0.44 | 0.88 | 0.001 |
| | M | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Vitamin B12 Deficiency | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Vitamin D Deficiency | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Dyslipidemia | Mi | 2 | (4.87) | 0 | (0) | 2 | (5) | 2 | (5.4) | 0 | (0) | 6 | (2.62) | 0.15 | 0.93 | 0.06 |
| Hypercholesterolemia | Mi | 2 | (4.87) | 2 | (5) | 3 | (7.5) | 1 | (2.7) | 0 | (0) | 8 | (3.49) | 0.97 | 0.34 | 0.06 |
| Hyperglycemia | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Hypertriglyceridemia | Mi | 3 | (7.31) | 4 | (10) | 1 | (2.5) | 3 | (8.1) | 0 | (0) | 11 | (4.8) | 0.66 | 0.26 | 0.02 |
| Obesity | Mi | 0 | (0) | 1 | (2.5) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.30 | 0.33 | |
| Insulin Resistance | Mi | 2 | (4.87) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.15 | | 0.06 |
| Metabolic Syndrome | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Overweight | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Disorders of the ear and labyrinth | Total | 1 | (2.43) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 3 | (1.31) | 0.32 | 0.16 | 0.18 |
| | Mi | 1 | (2.43) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 3 | (1.31) | 0.32 | 0.16 | 0.18 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Ear pain | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Ear disorder | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Vertigo | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|---------------------------------|--------------|--------|---------|-------|-------|--------|--------|-------|---------|-------|---------|-------|---------|-------------------|-------------------|----------------|
| Disorders of the immune system | Total | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Hypersensitivity | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Disorders of the nervous system | Total | 17 | (41.46) | 16 | (40) | 16 | (40) | 16 | (43.24) | 17 | (23.94) | 82 | (35.8) | 0.89 | 0.77 | 0.05 |
| | Mi | 15 | (36.58) | 16 | (40) | 15 | (37.5) | 14 | (37.83) | 14 | (19.71) | 74 | (32.31) | 0.75 | 0.97 | 0.05 |
| | Mo | 6 | (14.63) | 1 | (2.5) | 2 | (5) | 4 | (10.81) | 3 | (4.22) | 16 | (6.98) | 0.05 | 0.34 | 0.05 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Ageusia | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Anosmia | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Headache | Mi | 14 | (34.14) | 14 | (35) | 15 | (37.5) | 14 | (37.83) | 12 | (16.9) | 69 | (30.13) | 0.93 | 0.97 | 0.03 |
| Headache | Mo | 5 | (12.19) | 1 | (2.5) | 1 | (2.5) | 4 | (10.81) | 3 | (4.22) | 14 | (6.11) | 0.09 | 0.13 | 0.11 |
| Bruise | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Memory impairment | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Dizziness | Mi | 0 | (0) | 3 | (7.5) | 0 | (0) | 1 | (2.7) | 1 | (1.4) | 5 | (2.18) | 0.07 | 0.29 | 0.44 |
| Migraine | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Paresthesia | Mi | 2 | (4.87) | 0 | (0) | 2 | (5) | 1 | (2.7) | 0 | (0) | 5 | (2.18) | 0.15 | 0.60 | 0.06 |
| Loss of muscle strength | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | 0.30 | 0.29 | |
| Guillain-Barré syndrome | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Drowsiness | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Vertigo | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Endocrine disorders | Total | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Hyperprolactinemia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Hypothyroidism | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|---------------------------------|--------------|--------|---------|-------|--------|--------|--------|-------|---------|-------|---------|-------|---------|-------------------|-------------------|----------------|
| Gastrointestinal disorders | Total | 13 | (31.7) | 7 | (17.5) | 16 | (40) | 7 | (18.91) | 15 | (21.12) | 58 | (25.32) | 0.13 | 0.04 | 0.21 |
| | Mi | 11 | (26.82) | 7 | (17.5) | 15 | (37.5) | 7 | (18.91) | 12 | (16.9) | 52 | (22.7) | 0.31 | 0.07 | 0.21 |
| | Mo | 3 | (7.31) | 0 | (0) | 1 | (2.5) | 0 | (0) | 4 | (5.63) | 8 | (3.49) | 0.08 | 0.33 | 0.72 |
| | S | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Dental caries | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Colitis | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| Colitis | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Diarrhea | Mi | 2 | (4.87) | 3 | (7.5) | 3 | (7.5) | 1 | (2.7) | 2 | (2.81) | 11 | (4.8) | 0.62 | 0.34 | 0.57 |
| Diarrhea | Mo | 2 | (4.87) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 3 | (1.31) | 0.15 | | 0.27 |
| Dyspepsia | Mi | 0 | (0) | 1 | (2.5) | 1 | (2.5) | 1 | (2.7) | 1 | (1.4) | 4 | (1.74) | 0.30 | 0.95 | 0.44 |
| Dyspepsia | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Abdominal distension | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (5.4) | 0 | (0) | 2 | (0.87) | | 0.13 | |
| Abdominal pain | Mi | 0 | (0) | 1 | (2.5) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.30 | 0.33 | |
| Lower abdominal pain | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Periodontal disease | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Gastroesophageal reflux disease | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Gastroesophageal reflux disease | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Gastritis | Mi | 1 | (2.43) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.32 | 0.33 | 0.18 |
| Glossitis | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Inguinal hernia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Food poisoning | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Nausea | Mi | 1 | (2.43) | 1 | (2.5) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 4 | (1.74) | 0.98 | 0.33 | 0.69 |
| Odynophagia | Mi | 4 | (9.75) | 1 | (2.5) | 7 | (17.5) | 2 | (5.4) | 3 | (4.22) | 17 | (7.42) | 0.17 | 0.09 | 0.24 |
| Odynophagia | Mo | 1 | (2.43) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.32 | 0.33 | 0.18 |
| Acute pancreatitis | S | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Rectal polyp | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Irritable bowel syndrome | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 1 | (1.4) | 2 | (0.87) | | 0.29 | 0.44 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|--|--------------|-----------|----------------|----------|-------------|-----------|-------------|----------|----------------|-----------|----------------|-----------|----------------|-------------------|-------------------|----------------|
| Vomiting | Mi | 1 | (2.43) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.98 | | 0.18 |
| Aphthous ulcer | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| General disorders and administration site conditions | Total | 25 | (60.97) | 8 | (20) | 14 | (35) | 8 | (21.62) | 18 | (25.35) | 73 | (31.87) | 0.0002 | 0.19 | 0.0002 |
| | Mi | 24 | (58.53) | 8 | (20) | 14 | (35) | 7 | (18.91) | 17 | (23.94) | 70 | (30.56) | 0.0004 | 0.11 | 0.0003 |
| | Mo | 2 | (4.87) | 0 | (0) | 0 | (0) | 1 | (2.7) | 1 | (1.4) | 4 | (1.74) | 0.15 | 0.29 | 0.27 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Asthenia | Mi | 1 | (2.43) | 2 | (5) | 3 | (7.5) | 4 | (10.81) | 3 | (4.22) | 13 | (5.67) | 0.54 | 0.61 | 0.62 |
| Axillary Pain | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Injection Site Pain | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Chest Pain | Mi | 16 | (39.02) | 5 | (12.5) | 0 | (0) | 0 | (0) | 10 | (14.08) | 31 | (13.53) | 0.006 | | 0.002 |
| Flu-like Illness | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Chill | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Fatigue | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| General Discomfort | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Chest Discomfort | Mi | 2 | (4.87) | 1 | (2.5) | 3 | (7.5) | 0 | (0) | 1 | (1.4) | 7 | (3.05) | 0.57 | 0.08 | 0.27 |
| Fever | Mi | 5 | (12.19) | 0 | (0) | 4 | (10) | 2 | (5.4) | 1 | (1.4) | 12 | (5.24) | 0.02 | 0.45 | 0.01 |
| Dry Skin | Mi | 3 | (7.31) | 0 | (0) | 4 | (10) | 1 | (2.7) | 4 | (5.63) | 12 | (5.24) | 0.08 | 0.19 | 0.72 |
| Asthenia | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Axillary Pain | Mi | 5 | (12.19) | 1 | (2.5) | 2 | (5) | 2 | (5.4) | 6 | (8.45) | 16 | (6.98) | 0.09 | 0.93 | 0.52 |
| Injection Site Pain | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | 0.32 | 0.29 | 0.18 |
| Chest Pain | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| Musculoskeletal and connective tissue disorders | Total | 11 | (26.82) | 8 | (20) | 8 | (20) | 6 | (16.21) | 14 | (19.71) | 47 | (20.52) | 0.45 | 0.66 | 0.38 |
| | Mi | 9 | (21.95) | 8 | (20) | 6 | (15) | 6 | (16.21) | 14 | (19.71) | 43 | (18.77) | 0.82 | 0.88 | 0.77 |
| | Mo | 2 | (4.87) | 0 | (0) | 2 | (5) | 0 | (0) | 1 | (1.4) | 5 | (2.18) | 0.15 | 0.16 | 0.27 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Joint pain | Mi | 2 | (4.87) | 0 | (0) | 1 | (2.5) | 0 | (0) | 4 | (5.63) | 7 | (3.05) | 0.15 | 0.33 | 0.86 |
| Bruising | Mi | 1 | (2.43) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 2 | (2.81) | 5 | (2.18) | 0.98 | 0.29 | 0.90 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|-------------------------------|--------------|----------|---------------|----------|--------------|----------|--------------|----------|--------------|----------|---------------|-----------|---------------|-------------------|-------------------|----------------|
| Costochondritis | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Back pain | Mi | 1 | (2.43) | 1 | (2.5) | 2 | (5) | 0 | (0) | 2 | (2.81) | 6 | (2.62) | 0.98 | 0.16 | 0.90 |
| Back pain | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Pain in a limb | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Ligament sprain | Mi | 1 | (2.43) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.98 | | 0.18 |
| Ligament sprain | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Muscle spasms | Mi | 0 | (0) | 1 | (2.5) | 1 | (2.5) | 1 | (2.7) | 0 | (0) | 3 | (1.31) | 0.30 | 0.95 | |
| Muscle spasms | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Myalgia | Mi | 5 | (12.19) | 3 | (7.5) | 3 | (7.5) | 3 | (8.1) | 6 | (8.45) | 20 | (8.73) | 0.47 | 0.92 | 0.52 |
| Myalgia | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Osteopenia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Tendonitis | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 1 | (1.4) | 3 | (1.31) | 0.30 | 0.29 | 0.44 |
| Eye disorders | Total | 2 | (4.87) | 2 | (5) | 3 | (7.5) | 2 | (5.4) | 1 | (1.4) | 10 | (4.36) | 0.97 | 0.70 | 0.27 |
| | Mi | 2 | (4.87) | 2 | (5) | 2 | (5) | 2 | (5.4) | 1 | (1.4) | 9 | (3.93) | 0.97 | 0.93 | 0.27 |
| | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Allergic Conjunctivitis | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Conjunctivitis | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Eye pain | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| Photopsia | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Sty on the eyelid | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Conjunctival hemorrhage | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Iris hemorrhage | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Eye discomfort | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Abnormal sensation in the eye | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | 0.30 | 0.29 | |
| Psychiatric Disorders | Total | 1 | (2.43) | 1 | (2.5) | 4 | (10) | 0 | (0) | 4 | (5.63) | 10 | (4.36) | 0.98 | 0.04 | 0.43 |
| | Mi | 1 | (2.43) | 1 | (2.5) | 3 | (7.5) | 0 | (0) | 3 | (4.22) | 8 | (3.49) | 0.98 | 0.08 | 0.62 |
| | Mo | 0 | (0) | 0 | (0) | 2 | (5) | 0 | (0) | 2 | (2.81) | 4 | (1.74) | | 0.16 | 0.27 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|---|--------------|-----------|----------------|-----------|-------------|-----------|---------------|----------|----------------|-----------|----------------|-----------|----------------|-------------------|-------------------|----------------|
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Agitation | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Attention Impairment | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.30 | | 0.44 |
| Anxiety | Mi | 1 | (2.43) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 3 | (1.31) | 0.32 | 0.33 | 0.69 |
| Depression | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Stress | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Insomnia | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Panic Reaction | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Mixed Anxiety and Depressive Disorder | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Sleep Disorder | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Renal and Urinary Disorders | Total | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Renal Colic | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Dysuria | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Respiratory, thoracic, and mediastinal disorders | Total | 12 | (29.26) | 10 | (25) | 15 | (37.5) | 9 | (24.32) | 11 | (15.49) | 57 | (24.89) | 0.66 | 0.21 | 0.08 |
| | Mi | 12 | (29.26) | 10 | (25) | 15 | (37.5) | 9 | (24.32) | 10 | (14.08) | 56 | (24.45) | 0.66 | 0.21 | 0.05 |
| | Mo | 1 | (2.43) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 3 | (1.31) | 0.32 | 0.16 | 0.18 |
| | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| Dyspnea | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Pharyngolaryngeal pain | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (5.4) | 0 | (0) | 2 | (0.87) | | 0.13 | |
| Pharyngolaryngeal pain | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Pharyngeal erythema | Mi | 1 | (2.43) | 5 | (12.5) | 2 | (5) | 1 | (2.7) | 0 | (0) | 9 | (3.93) | 0.08 | 0.60 | 0.18 |
| Epistaxis | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Pharyngotonsillitis | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 3 | (8.1) | 2 | (2.81) | 5 | (2.18) | | 0.06 | 0.27 |
| Pharyngotonsillitis | Mi | 1 | (2.43) | 0 | (0) | 3 | (7.5) | 1 | (2.7) | 0 | (0) | 5 | (2.18) | 0.32 | 0.34 | 0.18 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX- PL p- value | IN AVX- PL p- value | AVX- AZ p- value |
|---------------------------------|--------------|-----------|---------------|----------|------------|-----------|-------------|----------|--------------|----------|---------------|-----------|--------------|---------------------------------|---------------------------------|---------------------------|
| Hypertrophy of nasal turbinates | Mi | 2 | (4.87) | 0 | (0) | 3 | (7.5) | 2 | (5.4) | 1 | (1.4) | 8 | (3.49) | 0.15 | 0.70 | 0.27 |
| Throat irritation | Mo | 1 | (2.43) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.32 | 0.33 | 0.18 |
| Nasal discomfort | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Nasopharyngitis | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (5.4) | 0 | (0) | 2 | (0.87) | | 0.13 | |
| Allergic rhinitis | Mi | 0 | (0) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 2 | (0.87) | | 0.16 | |
| Rhinorrhea | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Nasal dryness | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Cough | Mi | 6 | (14.63) | 4 | (10) | 6 | (15) | 5 | (13.51) | 3 | (4.22) | 24 | (10.48) | 0.52 | 0.85 | 0.05 |
| Cough | Mi | 0 | (0) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 2 | (0.87) | | 0.16 | |
| Laryngeal disorder | Mi | 4 | (9.75) | 1 | (2.5) | 2 | (5) | 3 | (8.1) | 5 | (7.04) | 15 | (6.55) | 0.17 | 0.58 | 0.61 |
| Dyspnea | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Pharyngolaryngeal pain | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Vascular Disorders | Total | 3 | (7.31) | 0 | (0) | 4 | (10) | 1 | (2.7) | 3 | (4.22) | 11 | (4.8) | 0.08 | 0.19 | 0.48 |
| | Mi | 3 | (7.31) | 0 | (0) | 4 | (10) | 1 | (2.7) | 3 | (4.22) | 11 | (4.8) | 0.08 | 0.19 | 0.48 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Hypertensive crisis | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Peripheral Vascular Disease | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Hematoma | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| Hemorrhoids | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Hypertension | Mi | 1 | (2.43) | 0 | (0) | 3 | (7.5) | 1 | (2.7) | 0 | (0) | 5 | (2.18) | 0.32 | 0.34 | 0.18 |
| Hypotension | Mi | 1 | (2.43) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.32 | 0.33 | 0.18 |

SOC: System Organ Class; PT: Preferred Term; AE: adverse event; SEV: severity; Mi: mild; Mo: moderate; S: severe; AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S; IM: intramuscular; IN: intranasal; PL: placebo. p-value calculated from the comparison of proportions (Z-test).

Table 2S. Proportion of affected subjects by local adverse events of special interest at 7 days post-immunization.

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|--|-------|--------|---------|-------|--------|--------|--------|-------|-------|-------|---------|-------|---------|-------------------|-------------------|----------------|
| Subjects | | 41 | | 40 | | 40 | | 37 | | 71 | | 229 | | | | |
| Locally AE | Total | 17 | (41.46) | 6 | (15) | 7 | (17.5) | 2 | (5.4) | 12 | (16.9) | 44 | (19.21) | 0.008 | 0.09 | 0.004 |
| | Mi | 16 | (39.02) | 6 | (15) | 7 | (17.5) | 2 | (5.4) | 12 | (16.9) | 43 | (18.77) | 0.01 | 0.09 | 0.009 |
| | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Skin and Subcutaneous Tissue Disorders | Total | 0 | (0) | 1 | (2.5) | 1 | (2.5) | 0 | (0) | 2 | (2.81) | 4 | (1.74) | 0.30 | 0.33 | 0.27 |
| | Mi | 0 | (0) | 1 | (2.5) | 1 | (2.5) | 0 | (0) | 2 | (2.81) | 4 | (1.74) | 0.30 | 0.33 | 0.27 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Erythema | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Pruritus | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (2.81) | 3 | (1.31) | 0.30 | | 0.27 |
| General disorders and administration site conditions | Total | 17 | (41.46) | 5 | (12.5) | 0 | (0) | 0 | (0) | 10 | (14.08) | 32 | (13.97) | 0.003 | | 0.001 |
| | Mi | 16 | (39.02) | 5 | (12.5) | 0 | (0) | 0 | (0) | 10 | (14.08) | 31 | (13.53) | 0.006 | | 0.002 |
| | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Injection Site Pain | Mi | 16 | (39.02) | 5 | (12.5) | 0 | (0) | 0 | (0) | 10 | (14.08) | 31 | (13.53) | 0.006 | | 0.002 |
| Injection Site Pain | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Respiratory, thoracic, and mediastinal disorders | Total | 0 | (0) | 0 | (0) | 7 | (17.5) | 2 | (5.4) | 0 | (0) | 9 | (3.93) | | 0.09 | |
| | Mi | 0 | (0) | 0 | (0) | 7 | (17.5) | 2 | (5.4) | 0 | (0) | 9 | (3.93) | | 0.09 | |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Epistaxis | Mi | 0 | (0) | 0 | (0) | 3 | (7.5) | 1 | (2.7) | 0 | (0) | 4 | (1.74) | | 0.34 | |
| Pharyngeal erythema | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (5.4) | 0 | (0) | 2 | (0.87) | | 0.13 | |
| Nasal discomfort | Mi | 0 | (0) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 2 | (0.87) | | 0.16 | |
| Nasal dryness | Mi | 0 | (0) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 2 | (0.87) | | 0.16 | |

SOC: System Organ Class; PT: Preferred Term; AE: Adverse Event; SEV: Severity; Mi: Mild; Mo: Moderate; S: Severe, AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S; IM: Intramuscular; IN: Intranasal; PL: Placebo. P-value calculated from comparison of proportions (Z-test).

Table 3S. Proportion of affected subjects by systemic adverse events of special interest at 7 days post-immunization.

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|---|--------------|--------|---------|-------|-------|--------|--------|-------|---------|-------|---------|-------|---------|-------------------|-------------------|----------------|
| Subjects | | 41 | | 40 | | 40 | | 37 | | 71 | | 229 | | | | |
| Systemic AE | Total | 24 | (58.53) | 20 | (50) | 23 | (57.5) | 15 | (40.54) | 19 | (26.76) | 101 | (44.1) | 0.44 | 0.13 | 0.0009 |
| | Mi | 23 | (56.09) | 20 | (50) | 23 | (57.5) | 14 | (37.83) | 19 | (26.76) | 99 | (43.23) | 0.58 | 0.08 | 0.002 |
| | Mo | 3 | (7.31) | 1 | (2.5) | 2 | (5) | 2 | (5.4) | 2 | (2.81) | 10 | (4.36) | 0.31 | 0.93 | 0.26 |
| | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Traumatic injuries, poisonings, and complications of therapeutic procedures | Total | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Injection-Related Reaction | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Cardiac Disorders | Total | 0 | (0) | 0 | (0) | 1 | (2.5) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | | 0.95 | |
| | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | | 0.95 | |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Palpitations | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Tachycardia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| Skin and Subcutaneous Tissue Disorders | Total | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | | 0.33 | 0.44 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Dermatitis | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Hyperhidrosis | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Reproductive and breast disorders | Total | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 2 | (2.81) | 4 | (1.74) | 0.30 | 0.29 | 0.27 |
| | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (2.81) | 3 | (1.31) | 0.30 | | 0.27 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|------------------------------------|-------|--------|---------|-------|--------|--------|--------|-------|---------|-------|---------|-------|---------|-------------------|-------------------|----------------|
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 1 | (1.4) | 2 | (0.87) | | 0.29 | 0.44 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Dysmenorrhea | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Menstrual disorders | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.30 | | 0.44 |
| Menstrual disorders | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 1 | (1.4) | 2 | (0.87) | | 0.29 | 0.44 |
| Disorders of the ear and labyrinth | Total | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Vertigo | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Disorders of the nervous system | Total | 14 | (34.14) | 10 | (25) | 12 | (30) | 9 | (24.32) | 9 | (12.67) | 54 | (23.58) | 0.36 | 0.57 | 0.006 |
| | Mi | 13 | (31.7) | 10 | (25) | 12 | (30) | 9 | (24.32) | 8 | (11.26) | 52 | (22.7) | 0.50 | 0.57 | 0.007 |
| | Mo | 1 | (2.43) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (1.4) | 3 | (1.31) | 0.98 | | 0.69 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Headache | Mi | 13 | (31.7) | 9 | (22.5) | 12 | (30) | 9 | (24.32) | 7 | (9.85) | 50 | (21.83) | 0.35 | 0.57 | 0.003 |
| Headache | Mo | 1 | (2.43) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (1.4) | 3 | (1.31) | 0.98 | | 0.69 |
| Dizziness | Mi | 0 | (0) | 2 | (5) | 0 | (0) | 1 | (2.7) | 0 | (0) | 3 | (1.31) | 0.14 | 0.29 | |
| Paresthesia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| Loss of muscle strength | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | 0.30 | 0.29 | |
| Drowsiness | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Gastrointestinal disorders | Total | 6 | (14.63) | 3 | (7.5) | 7 | (17.5) | 1 | (2.7) | 2 | (2.81) | 19 | (8.29) | 0.30 | 0.03 | 0.01 |
| | Mi | 6 | (14.63) | 3 | (7.5) | 7 | (17.5) | 1 | (2.7) | 2 | (2.81) | 19 | (8.29) | 0.30 | 0.03 | 0.01 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Diarrhea | Mi | 1 | (2.43) | 0 | (0) | 2 | (5) | 1 | (2.7) | 0 | (0) | 4 | (1.74) | 0.32 | 0.60 | 0.18 |
| Lower abdominal pain | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Abdominal pain | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Nausea | Mi | 1 | (2.43) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (1.4) | 3 | (1.31) | 0.98 | | 0.69 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p-value | IN AVX-PL p-value | AVX-AZ p-value |
|--|-----------|--------|---------|-------|--------|--------|--------|-------|---------|-------|---------|-------|---------|-------------------|-------------------|----------------|
| Odynophagia | Mi | 4 | (9.75) | 0 | (0) | 5 | (12.5) | 0 | (0) | 0 | (0) | 9 | (3.93) | 0.04 | 0.02 | 0.007 |
| Vomiting | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| General disorders and administration site conditions | Total | 11 | (26.82) | 4 | (10) | 12 | (30) | 5 | (13.51) | 10 | (14.08) | 42 | (18.34) | 0.05 | 0.08 | 0.09 |
| | Mi | 11 | (26.82) | 4 | (10) | 12 | (30) | 4 | (10.81) | 10 | (14.08) | 41 | (17.9) | 0.05 | 0.03 | 0.09 |
| | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | 0.32 | 0.29 | 0.18 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Asthenia | Mi | 1 | (2.43) | 2 | (5) | 3 | (7.5) | 2 | (5.4) | 3 | (4.22) | 11 | (4.8) | 0.54 | 0.70 | 0.62 |
| Asthenia | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Axillary Pain | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Chills | Mi | 2 | (4.87) | 1 | (2.5) | 3 | (7.5) | 0 | (0) | 1 | (1.4) | 7 | (3.05) | 0.57 | 0.08 | 0.27 |
| Fatigue | Mi | 3 | (7.31) | 0 | (0) | 4 | (10) | 2 | (5.4) | 0 | (0) | 9 | (3.93) | 0.08 | 0.45 | 0.02 |
| General discomfort | Mi | 3 | (7.31) | 0 | (0) | 4 | (10) | 1 | (2.7) | 4 | (5.63) | 12 | (5.24) | 0.08 | 0.19 | 0.72 |
| Chest tightness | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Fever | Mi | 4 | (9.75) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 6 | (8.45) | 12 | (5.24) | 0.17 | 0.29 | 0.81 |
| Fever | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (2.7) | 0 | (0) | 1 | (0.43) | | 0.29 | |
| Musculoskeletal and connective tissue disorders | Total | 4 | (9.75) | 4 | (10) | 4 | (10) | 3 | (8.1) | 2 | (2.81) | 17 | (7.42) | 0.97 | 0.77 | 0.11 |
| | Mi | 3 | (7.31) | 4 | (10) | 3 | (7.5) | 3 | (8.1) | 2 | (2.81) | 15 | (6.55) | 0.66 | 0.92 | 0.26 |
| | Mo | 1 | (2.43) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 2 | (0.87) | 0.32 | 0.33 | 0.18 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Arthralgia | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (2.81) | 3 | (1.31) | 0.32 | | 0.90 |
| Back pain | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Back pain | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| Myalgia | Mi | 2 | (4.87) | 3 | (7.5) | 2 | (5) | 2 | (5.4) | 2 | (2.81) | 11 | (4.8) | 0.62 | 0.93 | 0.57 |
| Myalgia | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Muscle spasms | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 1 | (2.7) | 0 | (0) | 2 | (0.87) | 0.30 | 0.29 | |
| Respiratory, thoracic, and mediastinal disorders | Total | 6 | (14.63) | 9 | (22.5) | 4 | (10) | 5 | (13.51) | 0 | (0) | 24 | (10.48) | 0.36 | 0.63 | 0.0009 |
| | Mi | 6 | (14.63) | 9 | (22.5) | 4 | (10) | 5 | (13.51) | 0 | (0) | 24 | (10.48) | 0.36 | 0.63 | 0.0009 |

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX- PL p- value | IN AVX- PL p- value | AVX- AZ p- value |
|------------------------|-----|-----------|---------|-------|--------|-----------|-------|-------|---------|-------|-----|-------|--------|---------------------------------|---------------------------------|---------------------------|
| | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Pharyngolaryngeal pain | Mi | 1 | (2.43) | 5 | (12.5) | 0 | (0) | 1 | (2.7) | 0 | (0) | 7 | (3.05) | 0.08 | 0.29 | 0.18 |
| Pharyngolaryngeal pain | S | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| Throat irritation | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (5.4) | 0 | (0) | 2 | (0.87) | | 0.13 | |
| Rhinorrhea | Mi | 5 | (12.19) | 3 | (7.5) | 4 | (10) | 4 | (10.81) | 0 | (0) | 16 | (6.98) | 0.47 | 0.90 | 0.002 |
| Cough | Mi | 2 | (4.87) | 1 | (2.5) | 0 | (0) | 2 | (5.4) | 0 | (0) | 5 | (2.18) | 0.57 | 0.13 | 0.06 |
| Cough | Mo | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |

SOC: System Organ Class; PT: Preferred Term; AE: Adverse Event; SEV: Severity; Mi: Mild; Mo: Moderate; S: Severe; AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S; IM: Intramuscular; IN: Intranasal; PL: Placebo. p-value calculated from comparison of proportions (Z-test).

Table 4S. Proportion of subjects affected by adverse events associated with vaccination at 7 days post-immunization.

| SOC PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p | IN AVX-PL p | AVX-AZ p |
|--|--------------|--------|---------|-------|-------|--------|-------|-------|-------|-------|--------|-------|--------|-------------|-------------|----------|
| Subjects | | 41 | | 40 | | 40 | | 37 | | 71 | | 229 | | | | |
| Any AE | Total | 6 | (14.63) | 4 | (10) | 3 | (7.5) | 1 | (2.7) | 7 | (9.85) | 21 | (9.17) | 0.52 | 0.34 | 0.44 |
| | Mi | 6 | (14.63) | 4 | (10) | 3 | (7.5) | 1 | (2.7) | 7 | (9.85) | 21 | (9.17) | 0.52 | 0.34 | 0.44 |
| | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Skin and Subcutaneous Tissue Disorders | Total | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Pruritus | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.30 | | |
| Disorders of the nervous system | Total | 4 | (9.75) | 1 | (2.5) | 1 | (2.5) | 1 | (2.7) | 4 | (5.63) | 11 | (4.8) | 0.17 | 0.95 | 0.41 |
| | Mi | 3 | (7.31) | 1 | (2.5) | 1 | (2.5) | 1 | (2.7) | 3 | (4.22) | 9 | (3.93) | 0.31 | 0.95 | 0.48 |
| | Mo | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Headache | Mi | 3 | (7.31) | 1 | (2.5) | 1 | (2.5) | 1 | (2.7) | 2 | (2.81) | 8 | (3.49) | 0.31 | 0.95 | 0.26 |
| Headache | M | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.32 | | 0.69 |
| Drowsiness | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| Gastrointestinal disorders | Total | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| Odynophagia | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| General disorders and administration site conditions | Total | 5 | (12.19) | 3 | (7.5) | 0 | (0) | 0 | (0) | 7 | (9.85) | 15 | (6.55) | 0.47 | | 0.70 |
| | Mi | 5 | (12.19) | 3 | (7.5) | 0 | (0) | 0 | (0) | 7 | (9.85) | 15 | (6.55) | 0.47 | | 0.70 |
| | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |

| SOC | PT | SEV | IM AVX | % | IM PL | % | IN AVX | % | IN PL | % | IM AZ | % | Total | % | IM AVX-PL p | IN AVX-PL p | AVX-AZ p |
|-----|--|--------------|--------|---------|-------|-------|--------|-------|-------|-----|-------|--------|-------|--------|-------------|-------------|----------|
| | | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | Asthenia | Mi | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (1.4) | 2 | (0.87) | 0.30 | | 0.44 |
| | Injection Site Pain | Mi | 5 | (12.19) | 3 | (7.5) | 0 | (0) | 0 | (0) | 6 | (8.45) | 14 | (6.11) | 0.47 | | 0.52 |
| | Chill | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | General Discomfort | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (1.4) | 1 | (0.43) | | | 0.44 |
| | Pirexia | Mi | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 2 | (2.81) | 2 | (0.87) | | | 0.27 |
| | Musculoskeletal and connective tissue disorders | Total | 1 | (2.43) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 3 | (1.31) | 0.32 | 0.16 | 0.18 |
| | | Mi | 1 | (2.43) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 3 | (1.31) | 0.32 | 0.16 | 0.18 |
| | | M | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | Arthralgia | Mi | 1 | (2.43) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 1 | (0.43) | 0.32 | | 0.18 |
| | Myalgia | Mi | 0 | (0) | 0 | (0) | 2 | (5) | 0 | (0) | 0 | (0) | 2 | (0.87) | | 0.16 | |
| | Respiratory, thoracic, and mediastinal disorders | Total | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |
| | | Mo | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | | S | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | 0 | (0) | | | |
| | Rhinorrhea | Mi | 0 | (0) | 0 | (0) | 1 | (2.5) | 0 | (0) | 0 | (0) | 1 | (0.43) | | 0.33 | |

SOC: System Organ Class (clasificación de eventos por órganos y sistemas); PT: Preferred Term (término preferido); EA: Adverse Event (evento adverso); SEV: severity (severidad); Mi: mild (leve); Mo: moderate (moderado); S: severe (severo), AVX: AVX/COVID-12; AZ: AZ/ChAdOx-1-S; IM: intramuscular; IN: intranasal; PL: placebo. P value calculated from comparison of proportions (Z-test).

Table 5S. Antibody titers throughout the study in subjects vaccinated with AVX/COVID-12 via intramuscular route.

| IM AVX/COVID-12 | | | | | | |
|--|-------------|---------------|-----------------|----------------|----------------|-----------------|
| | Baseline | Day 14 | Day 42 | Day 90 | Day 180 | Day 365 |
| Volunteers | 41 | 38 | 38 | 39 | 39 | 36 |
| Antibody titers IgG against spike protein | | | | | | |
| GM | 227.06 | 2171.4 | 1489 | 1399.7 | 1013.4 | 1514.2 |
| CI | 166 - 310.5 | 1609.2 - 2930 | 1083.8 - 2045.9 | 977.4 - 2004.4 | 651.4 - 1576.4 | 1054.2 - 2174.8 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Wuhan-1 neutralizing titers | | | | | | |
| GM | 37.2 | 308.7 | 509.7 | 372.5 | 382.8 | 513.9 |
| CI | 28.8 - 48.2 | 205.5 - 463.6 | 347.4 - 747.8 | 226.2 - 613.6 | 217.2 - 674.7 | 332 - 795.6 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Delta neutralizing titers | | | | | | |
| GM | 20.2 | 68.3 | 87.4 | 118.2 | 150.1 | 211.5 |
| CI | 17.8 - 23.1 | 45.9 - 101.6 | 55.3 - 138.2 | 71.2 - 196.1 | 91.5 - 246.1 | 132.3 - 337.9 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Alpha neutralizing titers | | | | | | |
| GM | 39.5 | 292.68 | 742.6 | 452.2 | 437.3 | 372.7 |
| CI | 30 - 52 | 209.1 - 409.7 | 443.3 - 1244 | 281.3 - 726.8 | 255.7 - 747.7 | 234.5 - 592.5 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Beta neutralizing titers | | | | | | |
| GM | 24.8 | 62.4 | 89.1 | 103.4 | 110.4 | 244.3 |
| CI | 20.8 - 29.7 | 42.5 - 91.7 | 55 - 144.2 | 62.7 - 170.5 | 67.1 - 181.9 | 151 - 395.4 |
| p-Value | | 0.002 | <0.001 | <0.001 | <0.001 | <0.001 |
| BA.2 neutralizing titers* | | | | | | |
| GM | 23.6 | 88.2 | ND | ND | ND | ND |
| CI | 20.3 - 27.5 | 55.6 - 139.7 | | | | |
| p-Value | | <0.001 | | | | |
| BA.5 neutralizing titers* | | | | | | |
| GM | 23 | 143 | ND | ND | ND | ND |
| CI | 19.7 - 26.9 | 94.5 - 216.3 | | | | |
| p-Value | | <0.001 | | | | |

*Sample size n=39, AVX: AVX/COVID-12; IM: intramuscular; ND: not determined; GM: geometric mean; CI: confidence interval. Comparison of GM tested with Wilcoxon signed-rank test (paired), variable on logarithmic scale.

Table 6S. Antibody titers throughout the study in subjects vaccinated with AVX/COVID-12 intramuscularly who did not experience COVID-19 during the study.

| AVX/COVID-12 IM | | | | | |
|--|--------|--------|--------|---------|---------|
| | Day 14 | Day 42 | Day 90 | Day 180 | Day 365 |
| Sujetos | 34 | 28 | 25 | 15 | 12 |
| Antibody titers IgG against spike protein | | | | | |
| GM | 2056.2 | 1226.6 | 1022 | 388.6 | 1133.9 |

| | | | | | |
|------------------------------------|-----------------|----------------|---------------|---------------|----------------|
| CI | 1496.4 - 2825.6 | 844.3 - 1782.1 | 651.5 - 1603 | 197.8 - 763.4 | 463 - 2776.8 |
| Wuhan-1 neutralizing titers | | | | | |
| GM | 289 | 404.3 | 286.3 | 142.4 | 466.9 |
| CI | 185.9 - 449.1 | 258.1 - 633.4 | 158.2 - 518 | 63.9 - 317.6 | 164.7 - 1323.4 |
| Delta neutralizing titers | | | | | |
| GM | 60.6 | 57.8 | 70.4 | 57.6 | 201.8 |
| CI | 39.7 - 92.3 | 35.9 - 93.1 | 40.1 - 123.7 | 34.3 - 96.8 | 70.3 - 579.1 |
| Alpha neutralizing titers | | | | | |
| GM | 286.4 | 603.1 | 346.9 | 192.1 | 338.7 |
| CI | 197.2 - 416.1 | 328.2 - 1107.8 | 188.9 - 636.9 | 79.1 - 466.4 | 108.7 - 1055.4 |
| Beta neutralizing titers | | | | | |
| GM | 55.3 | 70.5 | 58.9 | 44.7 | 226.9 |
| CI | 37.3 - 82.1 | 40.4 - 122.8 | 33.3 - 104 | 25 - 80 | 71.3 - 721.3 |
| BA.2 neutralizing titers | | | | | |
| GM | 76.6 | ND | ND | ND | ND |
| CI | 47.3 - 124 | | | | |
| BA.5 neutralizing titers | | | | | |
| GM | 130.1 | ND | ND | ND | ND |
| CI | 83.8 - 202.2 | | | | |

AVX: AVX/COVID-12; IM: intramuscular; ND: not determined; GM: geometric mean; CI: confidence interval. Comparison of GM using Wilcoxon signed-rank test (paired), variable on a logarithmic scale.

Table 7S. Antibody titers over the study duration in subjects vaccinated with AVX/COVID-12 via the intranasal route.

| AVX/COVID-12 IN | | | | | | |
|--|---------------|---------------|----------------|----------------|-----------------|-----------------|
| | Baseline | Day 14 | Day 42 | Day 90 | Day 180 | Day 365 |
| Volunteers | 40 | 39 | 38 | 38 | 37 | 36 |
| Antibody titers IgG against spike protein | | | | | | |
| GM | 253.7 | 1340.9 | 1181.6 | 917.8 | 1820.5 | 1763.7 |
| CI | 186.6 - 344.9 | 1034.5 - 1738 | 871.5 - 1601.9 | 619.2 - 1360.3 | 1203.2 - 2754.3 | 1158.3 - 2685.5 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Wuhan-1 neutralizing titers | | | | | | |
| GM | 28.7 | 219.5 | 362.9 | 305.2 | 759.6 | 721.5 |
| CI | 22.8 - 36 | 156.3 - 308.1 | 255.8 - 514.8 | 182.5 - 510.3 | 433.1 - 1332.3 | 438.9 - 1185.9 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Delta neutralizing titers | | | | | | |
| GM | 20.7 | 40.9 | 57.4 | 77 | 281.5 | 293.4 |
| CI | 19.7 - 21.7 | 29.5 - 56.8 | 39.7 - 83.1 | 46.3 - 128.2 | 165.5 - 478.9 | 177.6 - 484.8 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Alpha neutralizing titers | | | | | | |
| GM | 36.9 | 274.9 | 481.2 | 357.1 | 782 | 577.3 |
| CI | 27.5 - 49.5 | 201.1 - 375.8 | 299.7 - 772.6 | 205.7 - 619.9 | 453.4 - 1348.8 | 354.8 - 939.3 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| Beta neutralizing titers | | | | | | |
| GM | 20.8 | 49.3 | 89.1 | 67.8 | 206.1 | 355.9 |
| CI | 19.6 - 22.2 | 36.1 - 67.5 | 55 - 144.4 | 40.7 - 112.9 | 122.5 - 346.5 | 216.6 - 584.9 |
| p-Value | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| BA.2 neutralizing titers* | | | | | | |
| GM | 23.9 | 58 | ND | ND | ND | ND |
| CI | 20.2 - 28.4 | 38.7 - 87 | | | | |
| p-Value | | <0.001 | | | | |

BA.5 neutralizing titers*

| | | | | | | |
|---------|-------------|--------------|----|----|----|----|
| GM | 26 | 111.83 | ND | ND | ND | ND |
| CI | 21.3 - 31.7 | 76.4 - 163.5 | | | | |
| p-Value | | <0.001 | | | | |

*Sample size n=39, AVX: AVX/COVID-12; IM: intramuscular; ND: not determined; GM: geometric mean; CI: confidence interval. Comparison of GM tested with Wilcoxon signed-rank test (paired), variable on logarithmic scale.

Table 8S. Antibody titers throughout the study in subjects vaccinated with AVX/COVID-12 intranasally who did not experience COVID-19 during the study.

| AVX/COVID-12 IN | | | | | |
|--|----------------|----------------|---------------|----------------|----------------|
| | Day 14 | Day 42 | Day 90 | Day 180 | Day 365 |
| Subjects | 37 | 32 | 29 | 21 | 15 |
| Antibody titers IgG against spike protein | | | | | |
| GM | 1267.2 | 993.9 | 704.1 | 1417.1 | 1451.2 |
| CI | 977.7 - 1642.4 | 736.7 - 1340.9 | 470 - 1054.9 | 750.2 - 2676.9 | 597.3 - 3525.7 |
| Wuhan-1 neutralizing titers | | | | | |
| GM | 205.1 | 302.1 | 214.9 | 525.8 | 509.8 |
| CI | 145.7 - 288.6 | 216.4 - 421.8 | 124.8 - 370 | 221.3 - 1249 | 196.1 - 1325.1 |
| Delta neutralizing titers | | | | | |
| GM | 37 | 48.4 | 48.9 | 179.8 | 242.5 |
| CI | 27.1 - 50.5 | 33.5 - 69.9 | 30.2 - 79.2 | 81.9 - 394.7 | 90.2 - 652 |
| Alpha neutralizing titers | | | | | |
| GM | 262.5 | 363.3 | 248.8 | 571.1 | 359.3 |
| CI | 190.2 - 362.2 | 229.9 - 574.2 | 131.8 - 469.3 | 234.4 - 1391.6 | 139 - 928.9 |
| Beta neutralizing titers | | | | | |
| GM | 46.3 | 64.2 | 41.4 | 131.3 | 248.2 |
| CI | 33.7 - 63.6 | 40.9 - 101 | 25.9 - 66.2 | 60.6 - 284.2 | 99.3 - 620.2 |
| BA.2 neutralizing titers* | | | | | |
| GM | 51.2 | ND | ND | ND | ND |
| CI | 34.8 - 75.3 | | | | |
| BA.5 neutralizing titers* | | | | | |
| GM | 107.6 | ND | ND | ND | ND |
| CI | 72.2 - 160.2 | | | | |

*Sample size n=36, AVX: AVX/COVID-12; IN: intranasal; ND: not determined; GM: geometric mean; CI: confidence interval. GM comparison test with Wilcoxon signed-rank test, variable on a logarithmic scale.